WO2021093809A1 - 他发米帝司的晶型及其制备方法和用途 - Google Patents

他发米帝司的晶型及其制备方法和用途 Download PDF

Info

Publication number
WO2021093809A1
WO2021093809A1 PCT/CN2020/128376 CN2020128376W WO2021093809A1 WO 2021093809 A1 WO2021093809 A1 WO 2021093809A1 CN 2020128376 W CN2020128376 W CN 2020128376W WO 2021093809 A1 WO2021093809 A1 WO 2021093809A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystal form
crystalline
csv
csvii
csvi
Prior art date
Application number
PCT/CN2020/128376
Other languages
English (en)
French (fr)
Inventor
陈敏华
张婧
邹思茗
Original Assignee
苏州科睿思制药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州科睿思制药有限公司 filed Critical 苏州科睿思制药有限公司
Priority to CN202080007389.6A priority Critical patent/CN113242855B/zh
Priority to EP20886308.4A priority patent/EP4059926A4/en
Priority to JP2022527915A priority patent/JP2023503833A/ja
Publication of WO2021093809A1 publication Critical patent/WO2021093809A1/zh
Priority to US17/392,008 priority patent/US11795152B2/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the invention relates to the field of crystal chemistry. Specifically, it relates to the crystal form of Tafamidis and its preparation method and use.
  • Tafamidis free acid can stabilize transthyretin (TTR), prevent the dissociation of natural TTR tetramers into monomers, and inhibit the formation of TTR amyloid fibrils. It can be used to treat transthyretin amyloidosis. Hefamidis was developed by Pfizer and launched in the United States in 2019 under the trade name VYNDAMAX.
  • Compound I 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole, and its structural formula is as follows:
  • the crystal form is a solid in which the compound molecules are arranged in a three-dimensional order in the microstructure to form a crystal lattice.
  • the phenomenon of drug polymorphism refers to the existence of two or more different crystal forms of the drug. Because of different physical and chemical properties, different crystal forms of the drug may have different dissolution and absorption in the body, which may affect the clinical efficacy and safety of the drug to a certain extent. Especially for poorly soluble solid drugs, the crystal form will have a greater impact. Therefore, the crystal form of a drug must be an important content of drug research and also an important content of drug quality control.
  • drug co-crystal consists of two or more different molecules (one of which is the active pharmaceutical ingredient (API)) in the same crystal lattice through non-ionic bonds and non-co-polymers at a certain stoichiometric ratio.
  • Drug co-crystals provide an opportunity to design solid forms based on traditional bulk drug solid forms (such as salts and polymorphs).
  • the drug co-crystal can be used to improve the bioavailability and stability of the drug, and to improve the processing performance of the bulk drug in the drug production process.
  • Another advantage of drug co-crystals is that for some APIs that are difficult to salt due to lack of ionizable functional groups, drug co-crystals can provide more solid forms for them.
  • WO2016038500 discloses the crystalline form 1/2/4/6 of compound I, wherein the crystalline form 2 is a tetrahydrofuran solvate, the crystalline form 4 and the crystalline form 6 are unstable and are not suitable for formulation development, and the crystalline form 1 is compared with the crystalline form 2/4/6 is more stable.
  • the solubility of crystal form 1 is low.
  • WO2019175263 discloses an acetic acid solvate and a compound I crystal form of Compound I, but the inventors of the present application have discovered through research that the compound I crystal form cannot be stable in the formulation.
  • the inventors of the present application prepared the fumaric acid eutectic CSV, glutaric acid eutectic CSVI and adipic acid eutectic CSVII of compound I provided by the present invention, which have physical and chemical properties and preparation processing properties It has advantages in terms of bioavailability, such as melting point, solubility, moisture absorption, purification, stability, adhesion, compressibility, fluidity, dissolution in vivo and in vitro, and bioavailability.
  • the main purpose of the present invention is to provide a new crystal form of tafamidis and its preparation method and application.
  • the present invention provides a co-crystal CSV of compound I and fumaric acid (hereinafter referred to as "crystalline CSV").
  • the X-ray powder diffraction pattern of the crystalline CSV has characteristic peaks at the diffraction angle 2 ⁇ values of 13.4° ⁇ 0.2°, 22.8° ⁇ 0.2°, and 20.8° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form CSV has a diffraction angle 2 ⁇ value of 18.0° ⁇ 0.2°, 16.5° ⁇ 0.2°, 9.6° ⁇ 0.2° at 1, or 2, or 3, Characteristic peaks;
  • the X-ray powder diffraction pattern of the crystalline CSV has characteristic peaks at three of the diffraction angles 2 ⁇ of 18.0° ⁇ 0.2°, 16.5° ⁇ 0.2°, and 9.6° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form CSV has a diffraction angle 2 ⁇ value of 15.6° ⁇ 0.2°, 19.2° ⁇ 0.2°, 23.9° ⁇ 0.2°, at 1 location, or at 2 locations, or at 3 locations. Characteristic peaks; preferably, the X-ray powder diffraction pattern of the crystalline CSV has characteristic peaks at three of the diffraction angles 2 ⁇ of 15.6° ⁇ 0.2°, 19.2° ⁇ 0.2°, and 23.9° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystalline CSV has a diffraction angle 2 ⁇ value of 13.4° ⁇ 0.2°, 22.8° ⁇ 0.2°, 20.8° ⁇ 0.2°, 18.0° ⁇ 0.2° , 16.5° ⁇ 0.2°, 9.6° ⁇ 0.2°, 15.6° ⁇ 0.2°, 19.2° ⁇ 0.2°, 23.9° ⁇ 0.2° any 3, or 4, or 5, or 6, or 7 There are characteristic peaks at, or 8, or 9.
  • the crystal form CSV is crystal-free.
  • the molar ratio of compound I to fumaric acid in the crystalline CSV is 1:0.5.
  • the X-ray powder diffraction pattern of the crystalline CSV is basically as shown in FIG. 1.
  • thermogravimetric analysis chart of the crystalline CSV is basically as shown in Figure 2.
  • mass loss of about 0.2%
  • mass loss of about 16.2%
  • the differential scanning calorimetry diagram of the crystalline CSV is basically as shown in FIG. 6, when heated to 265.2° C., an endothermic signal begins to appear.
  • the present invention also provides a method for preparing the crystalline CSV, the preparation method comprising: placing tafamidis free acid and fumaric acid in ketones, esters, ethers or alcohols Stir in a mixed solvent with ethers to obtain crystal form CSV.
  • the molar ratio of the fumaric acid to the compound I is preferably 1:1-3:1.
  • the ketone solvent is preferably acetone; the ester is preferably ethyl acetate; the ether is preferably anisole and tetrahydrofuran; the alcohol is preferably n-butanol.
  • the stirring temperature is preferably 0-60°C, and the stirring time is preferably 3-10 days.
  • the crystal form CSV of the present invention has higher solubility. Especially in FeSSIF (simulated feeding state intestinal fluid), the solubility of the crystal form CSV of the present invention is 10 times that of the prior art WO2016038500 crystal form 1.
  • Compound I is a poorly water-soluble drug and belongs to BCS IV. Higher solubility is conducive to improving the absorption of drugs in the human body, improving bioavailability, and making the drugs play a better therapeutic effect; in addition, higher solubility can reduce the dose of the drug while ensuring the efficacy of the drug, thereby reducing the drug Side effects and improve the safety of medicines.
  • the crystal form CSV of the present invention has better dissolution in vitro.
  • pH6.8 phosphate buffered saline (PBS) the dissolution rate of crystalline CSV formulation is higher than that of WO2016038500 crystalline form 1.
  • Dissolution is an important prerequisite for the absorption of drugs.
  • a good in vitro dissolution indicates a higher degree of in vivo absorption of the drug and better exposure characteristics in the body, thereby increasing the bioavailability and improving the efficacy of the drug.
  • the crystalline CSV of the present invention has lower moisture absorption.
  • the test results show that the crystalline CSV of the present invention has a moisture-absorbing weight gain of 0.09% under 80% RH (Relative humidity) conditions, which is considered to have no or almost no moisture-absorbing properties.
  • the hygroscopicity directly affects the physical and chemical stability of the drug, and the high hygroscopicity can easily cause chemical degradation and crystal transformation.
  • high hygroscopicity will reduce the fluidity of the drug, thereby affecting the processing technology of the drug.
  • drugs with high hygroscopicity need to maintain low humidity during the production and storage process, which puts forward higher requirements on production and requires high costs.
  • high hygroscopicity can easily cause changes in the content of active ingredients in the drug, which affects the quality of the drug.
  • the low hygroscopicity crystal type is not harsh on the environment, reduces the cost of material production, storage and quality control, and has strong economic value.
  • the crystalline CSV bulk drugs and preparations provided by the present invention have good stability.
  • the crystalline CSV bulk drug is placed under the conditions of 25°C/60% relative humidity, and the crystalline form has not changed for at least 6 months, and the chemical purity is above 99.9%, and the purity remains basically unchanged during storage.
  • the crystal form of the crystalline CSV bulk drug remains unchanged for at least 6 months under the conditions of 40°C/75% relative humidity, and the crystal form has not changed for at least 2 months under the conditions of 60°C/75% relative humidity, and the chemical
  • the purity is above 99.9%, and the purity remains basically unchanged during storage.
  • the crystal form CSV is mixed with excipients to make a pharmaceutical preparation, it is placed under the condition of 40°C/75% relative humidity, and the crystal form does not change for at least 3 months. It shows that the crystalline CSV bulk drugs and preparations have better stability under accelerated conditions and more severe conditions. The stability of APIs and preparations under accelerated conditions and more severe conditions is very important for drugs.
  • Crystalline CSV bulk drugs and preparations have good stability under harsh conditions, which is beneficial to avoid the impact of deviation from the storage conditions on the label on the quality of the drug.
  • the crystalline CSV has good mechanical stability.
  • the crystalline CSV bulk drug has good physical stability after grinding.
  • the preparation process often requires the grinding and pulverization of the drug substance, and good physical stability can reduce the risk of crystallinity change and crystal transformation of the drug substance in the preparation process.
  • Crystalline CSV has good physical and chemical stability, ensuring consistent and controllable quality of raw materials and preparations, and minimizing changes in drug quality, bioavailability, and even side effects caused by changes in crystal form or impurities. .
  • the crystalline CSV provided by the present invention also has the following beneficial effects:
  • the crystalline CSV provided by the present invention has better compressibility.
  • the good compressibility of the crystalline CSV can effectively improve the hardness/fragility unqualified, chipping and other problems in the tableting process, making the formulation process more reliable, improving the appearance of the product, and improving the quality of the product.
  • the better compressibility can also increase the tableting speed and thus the production efficiency, and at the same time can reduce the cost of auxiliary materials used to improve the compressibility.
  • the present invention provides a eutectic crystal form CSVI of compound I and glutaric acid (hereinafter referred to as "crystalline form CSVI").
  • the X-ray powder diffraction pattern of the crystal form CSVI has characteristic peaks at the diffraction angle 2 ⁇ values of 14.1° ⁇ 0.2°, 19.1° ⁇ 0.2°, and 17.2° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form CSVI has a diffraction angle 2 ⁇ value of 10.0° ⁇ 0.2°, 22.5° ⁇ 0.2°, 24.3° ⁇ 0.2° at 1, or 2, or 3, Characteristic peaks;
  • the X-ray powder diffraction pattern of the crystal form CSVI has characteristic peaks at diffraction angles 2 ⁇ of 10.0° ⁇ 0.2°, 22.5° ⁇ 0.2°, and 24.3° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form CSVI has a diffraction angle 2 ⁇ value of 34.1° ⁇ 0.2°, 33.4° ⁇ 0.2°, 11.2° ⁇ 0.2°, 35.5° ⁇ 0.2°, or 2
  • characteristic peaks at, or 3, or 4 preferably, the X-ray powder diffraction pattern of the crystal form CSVI has a diffraction angle 2 ⁇ of 34.1° ⁇ 0.2°, 33.4° ⁇ 0.2°, 11.2° ⁇ 0.2°, There is a characteristic peak at 35.5° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form CSVI has a diffraction angle 2 ⁇ value of 14.1° ⁇ 0.2°, 19.1° ⁇ 0.2°, 17.2° ⁇ 0.2°, 10.0° ⁇ 0.2° , 22.5° ⁇ 0.2°, 24.3° ⁇ 0.2°, 34.1° ⁇ 0.2°, 33.4° ⁇ 0.2°, 11.2° ⁇ 0.2°, 35.5° ⁇ 0.2° any 3, or 4, or 5, Or 6, or 7, or 8, or 9, or 10 have characteristic peaks.
  • the X-ray powder diffraction pattern of the crystalline form CSVI is basically as shown in FIG. 15.
  • thermogravimetric analysis chart of the crystalline form CSVI is basically shown in FIG. 17, when it is heated to 200° C., it has a mass loss of about 17.5%, which corresponds to the removal of glutaric acid.
  • the differential scanning calorimetry diagram of the crystalline form CSVI is basically as shown in FIG. 18, when it is heated to 166.6° C., an endothermic peak begins to appear.
  • the present invention also provides a preparation method of the crystal form CSVI, the preparation method comprising: placing tafamidis free acid and glutaric acid in an ester solvent and stirring to obtain the crystal form CSVI.
  • the molar ratio of the glutaric acid to the compound I is preferably 2:1-3:1.
  • esters are preferably ethyl acetate.
  • the stirring temperature is preferably 0-40°C, and the stirring time is preferably 3-10 days.
  • the crystal form CSVI of the present invention has higher solubility.
  • Compound I is a poorly water-soluble drug and belongs to BCS IV.
  • Higher solubility is conducive to improving the absorption of the drug in the human body, increasing the bioavailability, and enabling the drug to exert a better therapeutic effect.
  • higher solubility can reduce the dose of the drug while ensuring the efficacy of the drug, thereby reducing the side effects of the drug and improving the safety of the drug.
  • the crystal form CSVI of the present invention has better dissolution in vitro.
  • PBS phosphate buffered saline solution
  • Tween 80 pH 6.8 + 1% Tween 80
  • PBS + 3% Tween 80 with pH 6.8 the dissolution rate of the crystalline CSVI preparation is higher than that of WO2016038500 crystalline form 1.
  • Dissolution is an important prerequisite for the absorption of drugs.
  • a good in vitro dissolution indicates a higher degree of in vivo absorption of the drug and better exposure characteristics in the body, thereby increasing the bioavailability and improving the efficacy of the drug.
  • the crystal form CSVI of the present invention has lower moisture absorption properties.
  • the test results show that the crystal form CSVI of the present invention has a moisture-absorbing weight gain of 0.21% under 80% RH conditions, which is slightly moisture-absorbing.
  • the hygroscopicity directly affects the physical and chemical stability of the drug, and the high hygroscopicity can easily cause chemical degradation and crystal transformation.
  • high hygroscopicity will reduce the fluidity of the drug, thereby affecting the processing technology of the drug.
  • drugs with high hygroscopicity need to maintain low humidity during the production and storage process, which puts forward higher requirements on production and requires high costs.
  • high hygroscopicity can easily cause changes in the content of active ingredients in the drug, which affects the quality of the drug.
  • the low hygroscopicity crystal type is not harsh on the environment, reduces the cost of material production, storage and quality control, and has strong economic value.
  • the crystalline CSVI bulk drug provided by the present invention has good stability.
  • the crystal form of CSVI bulk drug is placed under the condition of 25°C/60% relative humidity, the crystal form has not changed for at least 6 months, and the chemical purity is above 99.9%, and the purity remains basically unchanged during storage. It shows that the crystalline CSVI bulk drug has good stability under long-term conditions, which is conducive to the storage of the drug.
  • the crystal form of the crystalline CSVI bulk drug remains unchanged for at least 6 months under the conditions of 40°C/75% relative humidity, and the crystal form has not changed for at least 2 months under the conditions of 60°C/75% relative humidity, and the chemical
  • the purity is above 99.9%, and the purity remains basically unchanged during storage. It shows that the crystalline CSVI bulk drug has better stability under accelerated conditions and more severe conditions. The stability of the drug substance under accelerated conditions and more severe conditions is very important for the drug. During the storage, transportation, and production of raw materials, high temperature and high humidity conditions such as seasonal differences, climatic differences in different regions, and weather factors will cause high temperature and high humidity conditions.
  • the crystalline CSVI bulk drug has good stability under harsh conditions, which is beneficial to avoid the impact of deviation from the storage conditions on the label on the quality of the drug.
  • Crystal form CSVI has good physical and chemical stability, ensuring consistent and controllable quality of raw materials and preparations, and minimizing changes in drug quality, bioavailability, and even toxic side effects caused by changes in crystal form or impurities. .
  • the present invention provides a eutectic crystal form CSVII of compound I and adipic acid (hereinafter referred to as "crystal form CSVII").
  • the X-ray powder diffraction pattern of the crystal form CSVII has characteristic peaks at diffraction angle 2 ⁇ values of 13.9° ⁇ 0.2°, 18.8° ⁇ 0.2°, and 25.6° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystalline form CSVII has a diffraction angle 2 ⁇ value of 24.1° ⁇ 0.2°, 11.3° ⁇ 0.2°, 22.7° ⁇ 0.2° at 1, or 2, or 3. Characteristic peaks; preferably, the X-ray powder diffraction pattern of the crystalline form CSVII has characteristic peaks at diffraction angles 2 ⁇ of 24.1° ⁇ 0.2°, 11.3° ⁇ 0.2°, and 22.7° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystalline form CSVII has a diffraction angle 2 ⁇ value of 17.2° ⁇ 0.2°, 9.8° ⁇ 0.2°, 17.0° ⁇ 0.2°, at 1 place, or at 2 places, or at 3 places. Characteristic peaks; preferably, the X-ray powder diffraction pattern of the crystalline form CSVII has characteristic peaks at diffraction angles 2 ⁇ of 17.2° ⁇ 0.2°, 9.8° ⁇ 0.2°, and 17.0° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form CSVII has a diffraction angle 2 ⁇ value of 13.9° ⁇ 0.2°, 18.8° ⁇ 0.2°, 25.6° ⁇ 0.2°, 24.1° ⁇ 0.2° , 11.3° ⁇ 0.2°, 22.7° ⁇ 0.2°, 17.2° ⁇ 0.2°, 9.8° ⁇ 0.2°, 17.0° ⁇ 0.2° any 3, or 4, or 5, or 6, or 7 There are characteristic peaks at, or 8, or 9.
  • the X-ray powder diffraction pattern of the crystalline form CSVII is basically as shown in FIG. 25.
  • thermogravimetric analysis chart of the crystalline form CSVII is basically as shown in FIG. 26, which has a mass loss of about 19.0% when heated to 200°C, corresponding to the removal of adipic acid.
  • the differential scanning calorimetry diagram of the crystalline form CSVII is basically as shown in FIG. 27, and when it is heated to 166.7° C., an endothermic peak begins to appear.
  • the present invention also provides a preparation method of the crystal form CSVII, the preparation method comprising: placing tafamidis free acid and adipic acid in an ester solvent and stirring to obtain the crystal form CSVII.
  • the molar ratio of the adipic acid to the compound I is preferably 1:1-3:1.
  • esters are preferably ethyl acetate.
  • the stirring temperature is preferably 20-60°C, and the stirring time is preferably 3-10 days.
  • the crystal form CSVII of the present invention has higher solubility.
  • SGF simulated gastric juice
  • solubility of the crystal form CSVII of the present invention is more than 12 times that of the prior art WO2016038500 crystal form 1.
  • Compound I is a poorly water-soluble drug and belongs to BCS IV.
  • Higher solubility is conducive to improving the absorption of the drug in the human body, increasing the bioavailability, and enabling the drug to exert a better therapeutic effect.
  • higher solubility can reduce the dose of the drug while ensuring the efficacy of the drug, thereby reducing the side effects of the drug and improving the safety of the drug.
  • the crystal form CSVII of the present invention has better dissolution in vitro.
  • the dissolution rate of crystalline form CSVII preparation is higher than that of WO2016038500 crystalline form 1.
  • Dissolution is an important prerequisite for the absorption of drugs.
  • a good in vitro dissolution indicates a higher degree of in vivo absorption of the drug and better exposure characteristics in the body, thereby increasing the bioavailability and improving the efficacy of the drug.
  • the crystal form CSVII of the present invention has lower moisture absorption.
  • the test results show that the crystalline CSV of the present invention has a moisture-absorbing weight gain of 0.04% under 80% RH conditions, and it has no or almost no moisture-absorbing properties.
  • the hygroscopicity directly affects the physical and chemical stability of the drug, and the high hygroscopicity can easily cause chemical degradation and crystal transformation.
  • high hygroscopicity will reduce the fluidity of the drug, thereby affecting the processing technology of the drug.
  • drugs with high hygroscopicity need to maintain low humidity during the production and storage process, which puts forward higher requirements on production and requires high costs.
  • high hygroscopicity can easily cause changes in the content of active ingredients in the drug, which affects the quality of the drug.
  • the low hygroscopicity crystal type is not harsh on the environment, reduces the cost of material production, storage and quality control, and has strong economic value.
  • the crystalline CSVII bulk drugs and preparations provided by the present invention have good stability.
  • the crystal form CSVII bulk drug is placed under the condition of 25°C/60%RH, the crystal form has not changed for at least 3 months, and the chemical purity is above 99.9%, and the purity remains basically unchanged during storage.
  • the crystal form of the crystalline CSVII bulk drug remains unchanged for at least 3 months under the conditions of 40°C/75% relative humidity, and the crystal form has not changed for at least 2 months under the conditions of 60°C/75% relative humidity, and the chemical
  • the purity is above 99.9%, and the purity remains basically unchanged during storage. It shows that the crystalline CSVII bulk drug has better stability under accelerated conditions and more severe conditions. The stability of the drug substance under accelerated conditions and more severe conditions is very important for the drug. During the storage, transportation, and production of raw materials, high temperature and high humidity conditions such as seasonal differences, climatic differences in different regions, and weather factors will cause high temperature and high humidity conditions.
  • the crystalline CSVII bulk drug has good stability under harsh conditions, which is beneficial to avoid the impact of deviation from the storage conditions on the label on the quality of the drug.
  • Crystal form CSVII has good physical and chemical stability, ensuring consistent and controllable quality of raw materials and preparations, and minimizing changes in drug quality, bioavailability, and even side effects caused by changes in crystal form or impurities. .
  • crystal form CSVII provided by the present invention also has the following beneficial effects:
  • the crystal form CSVII provided by the present invention has better compressibility.
  • the good compressibility of the crystalline form CSVII can effectively improve the hardness/fragility unqualified, chipping and other problems in the tableting process, making the preparation process more reliable, improving the appearance of the product, and improving the quality of the product.
  • the better compressibility can also increase the tableting speed and thus the production efficiency, and at the same time can reduce the cost of auxiliary materials used to improve the compressibility.
  • the crystal form CSVII of the present invention has better adhesion.
  • the adhesion evaluation results show that the adsorption capacity of the crystal form CSVII is lower than that of the prior art crystal form.
  • the better adhesion of crystalline form CSVII can effectively improve or avoid sticky wheels and sticking caused by dry granulation and tablet compression, which is beneficial to improve product appearance and weight differences.
  • the better adhesion of crystal form CSVII can effectively reduce the agglomeration of raw materials, reduce the adsorption between materials and utensils, facilitate the dispersion of raw materials and the mixing with other auxiliary materials, and increase the uniformity of the mixing of materials and the final product. The content uniformity.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising an effective therapeutic amount of crystalline form CSV, crystalline form CSVI, crystalline form CSVII and pharmaceutically acceptable carriers or excipients.
  • the present invention provides the use of crystal form CSV, crystal form CSVI, and crystal form CSVII in the preparation of medicines for the treatment of diseases caused by transthyretin amyloidosis.
  • the present invention provides the use of crystal form CSV, crystal form CSVI, and crystal form CSVII in the preparation of drugs for treating transthyretin familial amyloid polyneuropathy and/or transthyretin cardiomyopathy.
  • the "stirring" is accomplished by conventional methods in the art, such as magnetic stirring or mechanical stirring, at a stirring speed of 50-1800 revolutions per minute, wherein the magnetic stirring is preferably 300-900 revolutions per minute, and mechanical stirring It is preferably 100-300 revolutions per minute.
  • the “separation” is accomplished by conventional methods in the art, such as centrifugation or filtration.
  • the operation of "centrifugation” is: place the sample to be separated in a centrifuge tube and centrifuge at a rate of 10,000 rpm until all the solids sink to the bottom of the centrifuge tube.
  • the "drying” can be performed at room temperature or higher.
  • the drying temperature is from room temperature to about 60°C, or to 50°C, or to 40°C.
  • the drying time can be 2-48 hours, or overnight. Drying is carried out in a fume hood, blast oven or vacuum oven.
  • crystalline or “polymorphic form” refers to a solid confirmed by X-ray powder diffraction characterization.
  • X-ray powder diffraction characterization a solid confirmed by X-ray powder diffraction characterization.
  • the physical and chemical properties discussed here can be characterized, and the experimental error depends on the condition of the instrument, the preparation of the sample, and the purity of the sample.
  • the X-ray powder diffraction pattern usually varies with the different instrument conditions.
  • the relative intensity of the diffraction peaks in the X-ray powder diffraction pattern may also change with the change of experimental conditions, so the order of the diffraction peak intensities cannot be the only or decisive factor.
  • the relative intensity of the diffraction peaks in the X-ray powder diffraction pattern is related to the preferred orientation of the crystals.
  • the intensity of the diffraction peaks shown in the present invention is illustrative rather than used for absolute comparison.
  • the experimental error of the position of the diffraction peak is usually 5% or less, and the error of these positions should also be taken into account, and an error of ⁇ 0.2° is usually allowed.
  • the overall angle of the diffraction peak will be shifted, and a certain shift is usually allowed.
  • the X-ray powder diffraction pattern of a crystal form in the present invention does not have to be exactly the same as the X-ray powder diffraction pattern in the embodiment referred to here, and any characteristic peaks in these patterns.
  • the crystal forms of the same or similar X-ray powder diffraction patterns fall within the scope of the present invention.
  • Those skilled in the art can compare the X-ray powder diffraction pattern listed in the present invention with the X-ray powder diffraction pattern of an unknown crystal form to confirm whether the two sets of images reflect the same or different crystal forms.
  • the crystalline form CSV, crystalline form CSVI, and crystalline form CSVII of the present invention are pure, and substantially no other crystalline forms are mixed.
  • substantially no when used to refer to a new crystal form means that this crystal form contains less than 20% by weight of other crystal forms, especially less than 10% by weight of other crystal forms, and even less. Other crystal forms that are less than 5% by weight, and even other crystal forms that are less than 1% by weight.
  • Figure 1 is an XRPD diagram of the crystalline CSV obtained according to Example 1
  • Figure 2 is a TGA diagram of the crystalline CSV obtained according to Example 1
  • Figure 3 is a 1 H NMR chart of the crystalline CSV obtained according to Example 1
  • Figure 4 is an XRPD diagram of the crystalline CSV obtained according to Example 2.
  • Figure 5 is an XRPD diagram of the crystalline CSV obtained according to Example 3.
  • Figure 6 is a DSC chart of the crystalline CSV obtained according to Example 4.
  • Figure 7 is a comparison of XRPD before and after the crystalline CSV is placed under different conditions (from top to bottom: placed at 60°C/75% relative humidity for 2 months, placed at 60°C/75% relative humidity closed for 2 Months, placed at 40°C/75% relative humidity open for 6 months, at 40°C/75% relative humidity closed for 6 months, 25°C/60% relative humidity open for 6 months, before placing)
  • Figure 8 is the XRPD comparison diagram of crystal CSV before and after grinding (from top to bottom: after grinding, before grinding)
  • Figure 9 is a comparison of XRPD before and after grinding of WO2016038500 crystal form 1 (from top to bottom: after grinding and before grinding)
  • Figure 10 is the DVS diagram of the crystalline CSV
  • Figure 11 is the XRPD comparison diagram of crystalline CSV before and after DVS test (from top to bottom: before DVS test, after DVS test)
  • Figure 12 is a comparison chart of XRPD of crystalline CSV before and after formulation (from top to bottom: formulation, crystalline CSV)
  • Figure 13 is the XRPD comparison chart of the stability of crystalline CSV formulations (from top to bottom: the double aluminum blister is placed at 25°C/60% relative humidity for 3 months, and the double aluminum blister is stored at 40°C/75% relative humidity. After 3 months of placement, before placement)
  • Figure 14 is the dissolution curve of crystalline CSV preparation and WO2016038500 crystalline form 1 in pH 6.8 phosphate buffered saline solution
  • Figure 15 is an XRPD diagram of the crystalline form CSVI obtained according to Example 13
  • Figure 16 is an XRPD diagram of the crystalline form CSVI obtained according to Example 14.
  • Figure 17 is a TGA diagram of the crystal form CSVI obtained according to Example 14.
  • Figure 18 is a DSC chart of the crystalline CSV obtained according to Example 14.
  • Figure 19 is a 1 H NMR chart of the crystalline form CSVI obtained according to Example 14
  • Figure 20 is a comparison of XRPD of crystalline CSVI before and after being placed under different conditions (from top to bottom: placed at 60°C/75% relative humidity closed for 2 months, placed at 40°C/75% relative humidity open for 6 Months, placed at 40°C/75% relative humidity closed for 6 months, placed at 25°C/60% relative humidity open for 6 months, before placing)
  • Figure 21 is the DVS diagram of crystal form CSVI
  • Figure 22 is the XRPD comparison diagram of crystal form CSVI before and after DVS test (from top to bottom: before DVS test, after DVS test)
  • Figure 23 is the dissolution profile of crystalline form CSVI preparation and WO2016038500 crystalline form 1 preparation in phosphate buffered saline (PBS) + 1% Tween 80 at pH 6.8
  • Figure 24 is the dissolution profile of crystalline form CSVI preparation and WO2016038500 crystalline form 1 preparation in phosphate buffered saline (PBS) + 3% Tween 80 at pH 6.8
  • Figure 25 is an XRPD diagram of the crystalline form CSVII obtained according to Example 19
  • Figure 26 is a TGA diagram of the crystalline form CSVII obtained according to Example 19
  • Figure 27 is a DSC chart of the crystalline form CSVII obtained according to Example 19
  • Figure 28 is a 1 H NMR chart of the crystalline form CSVII obtained according to Example 19
  • Figure 29 is a comparison of XRPD of crystalline form CSVII before and after being placed under different conditions (from top to bottom: placed at 60°C/75% relative humidity closed for 2 months, and placed at 40°C/75% relative humidity open 3 Months, placed at 40°C/75% relative humidity closed for 3 months, placed at 25°C/60% relative humidity open for 3 months, before placing)
  • Figure 30 is the DVS diagram of crystal form CSVII
  • Figure 31 is the XRPD comparison diagram of crystal form CSVII before and after DVS test (from top to bottom: before DVS test, after DVS test)
  • Figure 32 is the dissolution profile of crystalline form CSVII formulation and WO2016038500 crystalline form 1 formulation in phosphate buffered saline (PBS) + 1% Tween 80 at pH 6.8
  • the X-ray powder diffraction pattern of the sample except for the stability of the formulation of the present invention was collected on a Bruker D2 PHASER X-ray powder diffractometer.
  • the method parameters of the X-ray powder diffraction are as follows:
  • the X-ray powder diffraction pattern of the formulation stability of the present invention was collected on a Bruker D8 Discover X-ray powder diffractometer.
  • the parameters of the X-ray powder diffraction method described in the present invention are as follows:
  • the differential scanning calorimetry (DSC) chart of the present invention was collected on TA Q2000.
  • the method parameters of the DSC are as follows:
  • thermogravimetric analysis (TGA) chart of the present invention is collected on TA Q500.
  • the method parameters of the TGA are as follows:
  • the dynamic moisture adsorption (DVS) map of the present invention is collected on the Intrinsic dynamic moisture adsorption instrument produced by SMS (Surface Measurement Systems Ltd.).
  • the instrument control software is DVS-Intrinsic control software.
  • the method parameters of the dynamic moisture adsorption instrument are as follows:
  • Relative humidity range 0%RH-95%RH
  • the purity detection method in the present invention is shown in Table 2.
  • room temperature is not a specific temperature value, but refers to a temperature range of 10-30°C.
  • the compound I as a raw material includes, but is not limited to, solid form (crystalline or amorphous), oil form, liquid form and solution.
  • the compound I as a raw material is in a solid form.
  • the compound I used in the following examples can be prepared according to the prior art, for example, according to the method described in the WO2016038500 patent application.
  • the TGA of the crystalline CSV is shown in Figure 2.
  • 150°C there is a mass loss of about 0.2%
  • heating from 150°C to 225°C has a mass loss of 16.2%, corresponding to the removal of fumaric acid.
  • the 1 H NMR chart of the crystalline CSV is shown in Figure 3, and the peaking result is consistent with the structure of compound I, and the resonance peak at the chemical shift at 6.63 is the characteristic peak of fumaric acid. NMR results showed that the molar ratio of compound I to fumaric acid in the crystalline CSV was 1:0.5.
  • the obtained crystalline solid is the crystalline CSV of the present invention, and the X-ray powder diffraction results are shown in Figure 4 and Table 5.
  • the DSC is shown in Figure 6, when heated to 265.2°C, an endothermic signal begins to appear.
  • SGF simulated gastric juice
  • FaSSIF simulated fasting state intestinal fluid
  • FeSSIF simulated feeding state intestinal fluid
  • the crystalline CSV can be stable for at least 6 months under the conditions of 25°C/60%RH and 40°C/75%RH. It can be seen that the crystalline CSV can maintain good stability under long-term and accelerated conditions. It can be stable for at least 2 months under the condition of 60°C/75%RH. It can be seen that the crystalline CSV also has better stability under more severe conditions.
  • the crystalline form CSV of the present invention and WO2016038500 crystalline form 1 were respectively placed in a mortar, and manually ground for 5 minutes, and XRPD tests were performed before and after the grinding. The test results are shown in Figs. 8 and 9.
  • ENERPAC manual tablet press for tableting.
  • choose a ⁇ 6mm round flat punch add 80mg crystal form CSV and WO2016038500 crystal form 1, respectively, press 10kN to make round tablets, and place them at room temperature for 24 hours.
  • use a vernier caliper to measure the diameter (D) and thickness (L) of the tablet
  • use a tablet hardness tester to test its radial crushing force (hardness, H)
  • use the formula T 2H/ ⁇ DL*9.8 to calculate the powder
  • the tensile strength Under a certain pressure, the greater the tensile strength, the better the compressibility. The results are shown in Table 9.
  • the crystal form CSV of the present invention uses a dynamic moisture adsorption (DVS) instrument to test its hygroscopicity, cycle once at a relative humidity of 0-95%-0, record the quality change under each humidity, and before and after the DVS test Perform XRPD testing.
  • the DVS diagram of the crystalline CSV is shown in Fig. 10, and the XRPD before and after the moisture absorption measurement is shown in Fig. 11.
  • the crystalline CSV has a moisture absorption weight gain of 0.09% at 80% RH, which is considered to have no or almost no hygroscopicity.
  • moisture absorption weight gain is less than 15.0% but not less than 2.0%
  • moisture absorption weight gain is less than 2.0% but not less than 0.2%
  • weight gain is less than 0.2%
  • the crystalline CSV prepared by the present invention is prepared into a formulation using the formulation prescriptions and processes described in Table 10 and Table 11, and the XRPD before and after the crystalline CSV formulation is tested.
  • the XRPD comparison chart is shown in FIG. 12. The results show that the crystal form of CSV remains stable before and after the formulation process.
  • the crystalline form CSV and WO2016038500 crystalline form 1 prepared by the present invention are made into solid capsules using the formulation prescriptions and processes described in Table 13 and Table 14, and the accumulation of different time is tested in phosphate buffered saline (PBS) with pH 6.8
  • PBS phosphate buffered saline
  • the dissolution rate and test parameters are shown in Table 15, and the test results are shown in Table 16 and Figure 14.
  • the cumulative dissolution rate of the crystalline CSV in the pH 6.8 phosphate buffered saline solution is higher than that of WO2016038500 crystalline form 1.
  • the crystalline CSV of the present invention has better bioavailability.
  • the obtained crystalline solid is the crystal form CSVI of the present invention.
  • the X-ray powder diffraction pattern is shown in Fig. 15 and the X-ray powder diffraction data is shown in Table 17.
  • the solid was separated and dried under vacuum at 25° C. overnight.
  • the solid was placed in 20.0 mL of n-heptane solvent and suspended and stirred at room temperature for about 1 day.
  • the solid was separated and dried under vacuum at 25° C. overnight.
  • the obtained crystalline solid is the crystal form CSVI of the present invention.
  • the X-ray powder diffraction pattern is shown in Fig. 16, and the X-ray powder diffraction data is shown in Table 18.
  • the TGA chart of the crystalline CSVI is shown in Figure 17. When it is heated to 200°C, there is a mass loss of about 17.5%, which corresponds to the removal of glutaric acid.
  • the 1 H NMR chart of the crystalline form CSVI is shown in Figure 19, and the result is consistent with the structure of Compound I, in which the resonance peaks at the chemical shifts at 2.23 and 1.69 are characteristic peaks of glutaric acid.
  • the NMR results showed that the molar ratio of tafamidis and glutaric acid in the crystal form CSVI was 1:0.5.
  • solubility of the test is closer to the solubility in the human environment.
  • the crystal form CSVI can be stable for at least 6 months under the conditions of 25°C/60%RH and 40°C/75%RH. It can be seen that the crystal form CSVI can maintain good stability under long-term and accelerated conditions. It can be stable for at least 2 months under the condition of 60°C/75%RH. It can be seen that the stability of the crystal form CSVI is also very good under more severe conditions.
  • the crystal form CSVI of the present invention uses a dynamic moisture adsorption (DVS) instrument to test its hygroscopicity, cycle once at a relative humidity of 0-95%-0, record the mass change under each humidity, and before and after the DVS test Perform XRPD testing.
  • the DVS chart of the crystal form CSVI is shown in Fig. 21, and the XRPD before and after the moisture absorption measurement is shown in Fig. 22.
  • the crystal form CSVI has a moisture absorption weight gain of 0.21% under the condition of 80% RH, which is slightly hygroscopic.
  • the crystalline form CSVI of the present invention and WO2016038500 crystalline form 1 were prepared into solid tablets using the formulation and process described in Table 21, and were prepared at pH 6.8 phosphate buffered saline (PBS) + 1% Tween 80 and pH 6.8 phosphoric acid The cumulative dissolution rate was tested in salt buffered saline solution (PBS) + 3% Tween 80 at different times.
  • the test parameters are shown in Table 22 and Table 23, and the test results are shown in Table 24 ( Figure 23) and Table 25 ( Figure 24).
  • the obtained crystalline solid is the crystalline form CSVII described in the present invention.
  • the X-ray powder diffraction data is shown in Table 26, and the XRPD pattern is shown in Figure 25.
  • the TGA chart is shown in Figure 26. When it is heated to 200°C, there is a mass loss of about 19.0%, which corresponds to the removal of adipic acid.
  • the DSC chart is shown in Figure 27. When it was heated to 166.7°C, an endothermic peak began to appear.
  • the crystal form CSVII can be stable for at least 3 months under the conditions of 25°C/60%RH and 40°C/75%RH. It can be seen that the crystal form CSVII can maintain good stability under long-term and accelerated conditions. It can be stable for at least 2 months under the condition of 60°C/75%RH. It can be seen that the stability of the crystal form CSVII is also very good under more severe conditions.
  • ENERPAC manual tablet press for tableting.
  • choose ⁇ 6mm round flat punch add 80mg crystal form CSVII and WO2016038500 crystal form 1, respectively, press 10kN to make round tablets, and leave them at room temperature for 24h.
  • use a vernier caliper to measure the diameter (D) and thickness (L) of the tablet
  • use a tablet hardness tester to test its radial crushing force (hardness, H)
  • use the formula T 2H/ ⁇ DL*9.8 to calculate the powder tensile strength. Under a certain pressure, the greater the tensile strength, the better the compressibility.
  • Table 29 The results are shown in Table 29 below.
  • the crystal form CSVII of the present invention uses a dynamic moisture adsorption (DVS) instrument to test its moisture absorption, cycle once at a relative humidity of 0-95%-0, record the mass change under each humidity, and before and after the DVS test Perform XRPD testing.
  • the DVS chart of the crystal form CSVII is shown in Fig. 30, and the XRPD before and after the moisture absorption measurement is shown in Fig. 31.
  • the crystal form CSVII has a moisture absorption weight gain of 0.04% under 80% RH conditions, which is considered to have no or almost no moisture absorption.
  • the crystalline form CSVII and WO2016038500 crystalline form 1 prepared by the present invention were made into solid tablets using the formulation and process described in Table 31, and tested in phosphate buffered saline (PBS) + 1% Tween 80 at pH 6.8 The cumulative dissolution at different times, the test parameters are shown in Table 32, and the test results are shown in Table 33 and Figure 32.
  • PBS phosphate buffered saline
  • the cumulative dissolution rate of crystal form CSVII is higher than that of WO2016038500 crystal form 1 in pH 6.8 PBS + 1% Tween 80. Compared with WO2016038500 crystal form 1, the crystal form CSVI of the present invention has better bioavailability.
  • the WO2019175263 compound I crystal form was prepared into a preparation using the formulation prescription and process described in Table 34 and Table 35, and the XRPD before and after the crystal form preparation was tested. The results showed that the crystal form was unstable before and after the preparation process, and crystal transformation occurred during stirring at room temperature.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

公开了他发米帝司(化合物I)的新晶型及其制备方法，含有该晶型的药物组合物，以及该晶型在制备治疗转甲状腺素蛋白淀粉样病变引发的疾病的药物中的用途。该他发米帝司晶型比现有技术具有一种或多种改进的性质，对未来该药物的优化和开发具有重要价值。

Description

他发米帝司的晶型及其制备方法和用途 技术领域
本发明涉及晶体化学领域。具体而言，涉及他发米帝司的晶型及其制备方法和用途。
背景技术
他发米帝司游离酸能够稳定转甲状腺素素蛋白(TTR)，阻止天然TTR四聚体解离成单体，抑制TTR淀粉样原纤维形成，可用于治疗转甲状腺素素蛋白淀粉样病。他发米帝司由辉瑞开发，于2019年在美国上市，商品名为VYNDAMAX。
他发米帝司游离酸(以下称为“化合物I”)的化学名称为：6-羧基-2-(3,5-二氯苯基)-苯并噁唑，其结构式如下：
Figure PCTCN2020128376-appb-000001
晶型是化合物分子在微观结构中三维有序排列而形成晶格的固体，药物多晶型现象是指药物存在两种或两种以上的不同晶型。因为理化性质不同，药物的不同晶型可能在体内有不同的溶出、吸收，进而在一定程度上影响药物的临床疗效和安全性。特别是对难溶性固体药物，晶型的影响会更大。因此，药物晶型必然是药物研究的重要内容，也是药物质量控制的重要内容。
根据FDA药物共晶指南，药物共晶由两种或两种以上不同的分子(其中一个是活性药物成分(API))在同一个晶格中按一定的化学计量比通过非离子键和非共价键结合而成的晶体材料。药物共晶为在传统的原料药固体形态(如盐和多晶型)的基础上设计固体形态提供了机会。药物共晶可以用来提高药物的生物利用度和稳定性，并在药物生产过程中提高原料药的加工性能。药物共晶的另一个优点是，对于一些因缺少可电离官能团而难以成盐的原料药，药物共晶可为其提供更多的固态形式。
WO2016038500中披露了化合物I的晶型1/2/4/6，其中晶型2为四氢呋喃溶剂合物，晶型4和晶型6不稳定，不适宜制剂开发，晶型1相较于晶型2/4/6更加稳定。但本申请发明人经研究发现，晶型1溶解度较低。WO2019175263披露了化合物I的一个醋酸溶剂合物和一个化合物I晶型，但本申请发明人经研究发现，该化合物I晶型不能在制剂中稳定。
为克服现有技术的缺点，本申请的发明人制备了本发明提供的化合物I的富马酸共晶CSV、戊二酸共晶CSVI和己二酸共晶CSVII，其在理化性质，制剂加工性能及生物利用度等方面具有优势，例如在熔点，溶解度，引湿性，提纯作用，稳定性，黏附性，可压性，流动性，体内外溶出，生物有效性等方面中的至少一方面存在优势，特别是稳定性好、溶解度高、引湿性低、制剂溶出度高，解决了现有技术晶型存在的问题，对含他发米帝司的药物开发具有非常重要的意义。
发明内容
本发明的主要目的是提供他发米帝司的新晶型及其制备方法和用途。
根据本发明的目的，本发明提供化合物I与富马酸的共晶CSV(以下称作“晶型CSV”)。
一方面，使用Cu-Kα辐射，所述晶型CSV的X射线粉末衍射图在衍射角2θ值为13.4°±0.2°、22.8°±0.2°、20.8°±0.2°处有特征峰。
进一步地，所述晶型CSV的X射线粉末衍射图在衍射角2θ值为18.0°±0.2°、16.5°±0.2°、9.6°±0.2°中的1处、或2处、或3处有特征峰；优选地，所述晶型CSV的X射线粉末衍射图在衍射角2θ为18.0°±0.2°、16.5°±0.2°、9.6°±0.2°中的3处有特征峰。
进一步地，所述晶型CSV的X射线粉末衍射图在衍射角2θ值为15.6°±0.2°、19.2°±0.2°、23.9°±0.2°中的1处、或2处、或3处有特征峰；优选地，所述晶型CSV的X射线粉末衍射图在衍射角2θ为15.6°±0.2°、19.2°±0.2°、23.9°±0.2°中的3处有特征峰。
另一方面，使用Cu-Kα辐射，所述晶型CSV的X射线粉末衍射图在衍射角2θ值为13.4°±0.2°、22.8°±0.2°、20.8°±0.2°、18.0°±0.2°、16.5°±0.2°、9.6°±0.2°、15.6°±0.2°、19.2°±0.2°、23.9°±0.2°中的任意3处、或4处、或5处、或6处、或7处、或8处、或9处有特征峰。
非限制性地，晶型CSV为无水晶型。
非限制性地，晶型CSV中化合物I与富马酸的摩尔比为1:0.5。
非限制性地，晶型CSV的X射线粉末衍射图基本如图1所示。
非限制性地，晶型CSV的热重分析图基本如图2所示，其加热至150℃时，具有约0.2％的质量损失，从150℃加热到225℃，具有约16.2％的质量损失，对应富马酸的脱去。
非限制性地，晶型CSV的差示扫描量热分析图基本如图6所示，加热至265.2℃时，开始出现吸热信号。
根据本发明的目的，本发明还提供所述晶型CSV的制备方法，所述制备方法包括:将他发米帝司游离酸与富马酸置于酮类、酯类、醚类或醇类与醚类的混合溶剂中搅拌获得晶型CSV。
进一步的，所述富马酸与化合物I的摩尔比优选1:1-3:1。
进一步的，所述酮类溶剂优选丙酮；所述酯类优选乙酸乙酯；所述醚类优选苯甲醚和四氢呋喃；所述醇类优选正丁醇。
进一步的，所述搅拌的温度优选0-60℃，所述搅拌的时间优选3-10天。
本发明提供的晶型CSV具有以下有益效果：
(1)与现有技术相比，本发明晶型CSV具有更高的溶解度。特别是在FeSSIF(模拟进食状态肠液)中，本发明晶型CSV的溶解度是现有技术WO2016038500晶型1的10倍。
化合物I是水溶性差的药物，属于BCS IV。更高的溶解度有利于提高药物在人体内的吸收，提高生物利用度，使药物发挥更好的治疗作用；另外，更高的溶解度能够在保证药物疗效的同时，降低药物的剂量，从而降低药品的副作用并提高药品的安全性。
(2)与现有技术相比，本发明晶型CSV具有更优的体外溶出度。在pH6.8磷酸盐缓冲盐溶液(PBS)中，晶型CSV制剂溶出度高于WO2016038500晶型1。
不同的晶型可能导致药物在体内有不同的溶出速率，直接影响药物在体内的吸收、分布、代谢、排泄，最终因其生物利用度不同而导致临床药效的差异。溶出度是药物被吸收的重要前提，良好的体外溶出度预示药物的体内吸收程度较高，在体内暴露特性更好，从而提高生物利用度，提高药物的疗效。
(3)本发明晶型CSV具有较低的引湿性。测试结果表明，本发明晶型CSV在80％RH(Relative humidity，相对湿度)条件下引湿性增重为0.09％，属于无或几乎无引湿性。
引湿性直接影响药物的物理化学稳定性，引湿性高易引起化学降解和晶型转变。此外，引湿性高会降低药物的流动性，从而影响药物的加工工艺。不仅如此，引湿性高的药物在生产和保存过程中需要维持低的湿度，对生产提出了更高的要求，需要很高的成本。更重要的是，引湿性高容易造成药物中有效成分含量的变化，影响药物的质量。低引湿性晶型对环境要求不苛刻，降低了物料生产、保存和质量控制成本，具有很强的经济价值。
(4)本发明提供的晶型CSV原料药和制剂均具有良好的稳定性。晶型CSV原料药在25℃/60％相对湿度条件下放置，至少6个月晶型未发生变化，且化学纯度在99.9％以上，储存过程中纯度基本保持不变。晶型CSV与辅料混合做成药物制剂后，在25℃/60％相对湿度条件下放置，至少3个月晶型未发生变化。说明晶型CSV原料药和制剂在长期条件下具有较好的稳定性，有利于药物的储存。
同时，晶型CSV原料药在40℃/75％相对湿度条件下放置至少6个月晶型未发生变化，在60℃/75％相对湿度条件下至少2个月晶型未发生变化，且化学纯度均在99.9％以上，储存过程中纯度基本保持不变。晶型CSV与辅料混合做成药物制剂后，在40℃/75％相对湿度条件下放置，至少3个月晶型未发生变化。说明晶型CSV原料药和制剂在加速条件及更严苛的条件下，具有较好的稳定性。原料药和制剂在加速条件及更严苛的条件下的稳定性对于药物至关重要。原料药和制剂在储存、运输、生产过程中会遇到季节差异、不同地区气候差异和天气因素等带来的高温和高湿条件。晶型CSV原料药和制剂在苛刻的条件下具有较好的稳定性，有利于避免偏离标签上的贮藏条件对药物质量的影响。
同时，晶型CSV具有良好的机械稳定性。晶型CSV原料药研磨后具有良好的物理稳定性。制剂加工过程中常需要原料药的研磨粉碎，良好的物理稳定性能够降低制剂加工过程中原料药晶型结晶度改变和转晶的风险。
晶型的转变会导致药物的吸收发生变化，影响生物利用度，甚至引起药物的毒副作用。良好的化学稳定性可以确保在储存过程中基本没有杂质产生。晶型CSV具有良好的物理化学稳定性，保证原料药和制剂质量一致可控，最大程度地减少药物由于晶型改变或杂质产生引起的药物质量变化，生物利用度改变，甚至引起药物的毒副作用。
进一步地，本发明提供的晶型CSV还具有以下有益效果：
(1)与现有技术相比，本发明提供的晶型CSV具有更优的可压性。晶型CSV良好的可压性可以有效改善压片工艺中的硬度/脆碎度不合格、裂片等问题，使制剂工艺更为可靠，改善产品外观，提升产品质量。更优的可压性亦可提升压片速度进而提升生产效率，同时可减少用于改善可压性的辅料的成本支出。
根据本发明的目的，本发明提供化合物I与戊二酸的共晶晶型CSVI(以下称作“晶型CSVI”)。
一方面，使用Cu-Kα辐射，所述晶型CSVI的X射线粉末衍射图在衍射角2θ值为14.1°±0.2°、19.1°±0.2°、17.2°±0.2°处有特征峰。
进一步地，所述晶型CSVI的X射线粉末衍射图在衍射角2θ值为10.0°±0.2°、22.5°±0.2°、24.3°±0.2°中的1处、或2处、或3处有特征峰；优选地，所述晶型CSVI的X射线粉末衍射图在 衍射角2θ为10.0°±0.2°、22.5°±0.2°、24.3°±0.2°处有特征峰。
进一步地，所述晶型CSVI的X射线粉末衍射图在衍射角2θ值为34.1°±0.2°、33.4°±0.2°、11.2°±0.2°、35.5°±0.2°中的1处、或2处、或3处、或4处有特征峰；优选地，所述晶型CSVI的X射线粉末衍射图在衍射角2θ为34.1°±0.2°、33.4°±0.2°、11.2°±0.2°、35.5°±0.2°处有特征峰。
另一方面，使用Cu-Kα辐射，所述晶型CSVI的X射线粉末衍射图在衍射角2θ值为14.1°±0.2°、19.1°±0.2°、17.2°±0.2°、10.0°±0.2°、22.5°±0.2°、24.3°±0.2°、34.1°±0.2°、33.4°±0.2°、11.2°±0.2°、35.5°±0.2°中的任意3处、或4处、或5处、或6处、或7处、或8处、或9处、或10处有特征峰。
非限制性地，晶型CSVI的X射线粉末衍射图基本如图15所示。
非限制性地，晶型CSVI的热重分析图基本如图17所示，其加热至200℃时，具有约17.5％的质量损失，对应戊二酸的脱去。
非限制性地，晶型CSVI的差示扫描量热分析图基本如图18所示，其加热至166.6℃时，开始出现吸热峰。
根据本发明的目的，本发明还提供所述晶型CSVI的制备方法，所述制备方法包括:将他发米帝司游离酸与戊二酸置于酯类溶剂中搅拌获得晶型CSVI。
进一步的，所述戊二酸与化合物I的摩尔比优选2:1-3:1。
进一步的，所述酯类优选乙酸乙酯。
进一步的，所述搅拌的温度优选0-40℃，所述搅拌的时间优选3-10天。
本发明提供的晶型CSVI具有以下有益效果：
(1)与现有技术相比，本发明晶型CSVI具有更高的溶解度。
化合物I是水溶性差的药物，属于BCS IV。更高的溶解度有利于提高药物在人体内的吸收，提高生物利用度，使药物发挥更好的治疗作用。另外，更高的溶解度能够在保证药物疗效的同时，降低药物的剂量，从而降低药品的副作用并提高药品的安全性。
(2)与现有技术相比，本发明晶型CSVI具有更优的体外溶出度。在pH 6.8的磷酸盐缓冲盐溶液(PBS)+1％吐温80及pH 6.8的PBS+3％吐温80中，晶型CSVI制剂溶出度均高于WO2016038500晶型1。
不同的晶型可能导致药物在体内有不同的溶出速率，直接影响药物在体内的吸收、分布、代谢、排泄，最终因其生物利用度不同而导致临床药效的差异。溶出度是药物被吸收的重要前提，良好的体外溶出度预示药物的体内吸收程度较高，在体内暴露特性更好，从而提高生物利用度，提高药物的疗效。
(3)本发明晶型CSVI具有较低的引湿性。测试结果表明，本发明晶型CSVI在80％RH条件下引湿性增重为0.21％，属于略有引湿性。
引湿性直接影响药物的物理化学稳定性，引湿性高易引起化学降解和晶型转变。此外，引湿性高会降低药物的流动性，从而影响药物的加工工艺。不仅如此，引湿性高的药物在生产和保存过程中需要维持低的湿度，对生产提出了更高的要求，需要很高的成本。更重要的是，引湿性高容易造成药物中有效成分含量的变化，影响药物的质量。低引湿性晶型对环境要求不苛刻，降低了物料生产、保存和质量控制成本，具有很强的经济价值。
(4)本发明提供的晶型CSVI原料药具有良好的稳定性。晶型CSVI原料药在25℃/60％ 相对湿度条件下放置，至少6个月晶型未发生变化，且化学纯度在99.9％以上，储存过程中纯度基本保持不变。说明晶型CSVI原料药在长期条件下具有较好的稳定性，有利于药物的储存。
同时，晶型CSVI原料药在40℃/75％相对湿度条件下放置至少6个月晶型未发生变化，在60℃/75％相对湿度条件下至少2个月晶型未发生变化，且化学纯度均在99.9％以上，储存过程中纯度基本保持不变。说明晶型CSVI原料药在加速条件及更严苛的条件下，具有较好的稳定性。原料药在加速条件及更严苛的条件下的稳定性对于药物至关重要。原料药在储存、运输、生产过程中会遇到季节差异、不同地区气候差异和天气因素等带来的高温和高湿条件。晶型CSVI原料药在苛刻的条件下具有较好的稳定性，有利于避免偏离标签上的贮藏条件对药物质量的影响。
晶型的转变会导致药物的吸收发生变化，影响生物利用度，甚至引起药物的毒副作用。良好的化学稳定性可以确保在储存过程中基本没有杂质产生。晶型CSVI具有良好的物理化学稳定性，保证原料药和制剂质量一致可控，最大程度地减少药物由于晶型改变或杂质产生引起的药物质量变化，生物利用度改变，甚至引起药物的毒副作用。
根据本发明的目的，本发明提供化合物I与己二酸的共晶晶型CSVII(以下称作“晶型CSVII”)。
一方面，使用Cu-Kα辐射，所述晶型CSVII的X射线粉末衍射图在衍射角2θ值为13.9°±0.2°、18.8°±0.2°、25.6°±0.2°处有特征峰。
进一步地，所述晶型CSVII的X射线粉末衍射图在衍射角2θ值为24.1°±0.2°、11.3°±0.2°、22.7°±0.2°中的1处、或2处、或3处有特征峰；优选地，所述晶型CSVII的X射线粉末衍射图在衍射角2θ为24.1°±0.2°、11.3°±0.2°、22.7°±0.2°处有特征峰。
进一步地，所述晶型CSVII的X射线粉末衍射图在衍射角2θ值为17.2°±0.2°、9.8°±0.2°、17.0°±0.2°中的1处、或2处、或3处有特征峰；优选地，所述晶型CSVII的X射线粉末衍射图在衍射角2θ为17.2°±0.2°、9.8°±0.2°、17.0°±0.2°处有特征峰。
另一方面，使用Cu-Kα辐射，所述晶型CSVII的X射线粉末衍射图在衍射角2θ值为13.9°±0.2°、18.8°±0.2°、25.6°±0.2°、24.1°±0.2°、11.3°±0.2°、22.7°±0.2°、17.2°±0.2°、9.8°±0.2°、17.0°±0.2°中的任意3处、或4处、或5处、或6处、或7处、或8处、或9处有特征峰。
非限制性地，晶型CSVII的X射线粉末衍射图基本如图25所示。
非限制性地，晶型CSVII的热重分析图基本如图26所示，其加热至200℃时，具有约19.0％的质量损失，对应己二酸的脱去。
非限制性地，晶型CSVII的差示扫描量热分析图基本如图27所示，其加热至166.7℃时，开始出现吸热峰。
根据本发明的目的，本发明还提供所述晶型CSVII的制备方法，所述制备方法包括:将他发米帝司游离酸与己二酸置于酯类溶剂中搅拌获得晶型CSVII。
进一步的，所述己二酸与化合物I的摩尔比优选1:1-3:1。
进一步的，所述酯类优选乙酸乙酯。
进一步的，所述搅拌的温度优选20-60℃，所述搅拌的时间优选3-10天。
本发明提供的晶型CSVII具有以下有益效果：
(1)与现有技术相比，本发明晶型CSVII具有更高的溶解度。特别是在SGF(模拟胃液)中，本发明晶型CSVII的溶解度是现有技术WO2016038500晶型1的12倍多。
化合物I是水溶性差的药物，属于BCS IV。更高的溶解度有利于提高药物在人体内的吸收，提高生物利用度，使药物发挥更好的治疗作用。另外，更高的溶解度能够在保证药物疗效的同时，降低药物的剂量，从而降低药品的副作用并提高药品的安全性。
(2)与现有技术相比，本发明晶型CSVII具有更优的体外溶出度。在pH 6.8的PBS+1％吐温80中，晶型CSVII制剂溶出度高于WO2016038500晶型1。
不同的晶型可能导致药物在体内有不同的溶出速率，直接影响药物在体内的吸收、分布、代谢、排泄，最终因其生物利用度不同而导致临床药效的差异。溶出度是药物被吸收的重要前提，良好的体外溶出度预示药物的体内吸收程度较高，在体内暴露特性更好，从而提高生物利用度，提高药物的疗效。
(3)本发明晶型CSVII具有较低的引湿性。测试结果表明，本发明晶型CSV在80％RH条件下引湿性增重为0.04％，属于无或几乎无引湿性。
引湿性直接影响药物的物理化学稳定性，引湿性高易引起化学降解和晶型转变。此外，引湿性高会降低药物的流动性，从而影响药物的加工工艺。不仅如此，引湿性高的药物在生产和保存过程中需要维持低的湿度，对生产提出了更高的要求，需要很高的成本。更重要的是，引湿性高容易造成药物中有效成分含量的变化，影响药物的质量。低引湿性晶型对环境要求不苛刻，降低了物料生产、保存和质量控制成本，具有很强的经济价值。
(4)本发明提供的晶型CSVII原料药和制剂均具有良好的稳定性。晶型CSVII原料药在25℃/60％RH条件下放置，至少3个月晶型未发生变化，且化学纯度在99.9％以上，储存过程中纯度基本保持不变。晶型CSVII与辅料混合做成药物制剂后，在30℃/60％RH条件下放置，至少3个月晶型未发生变化。说明晶型CSVII原料药和制剂在长期条件下具有较好的稳定性，有利于药物的储存。
同时，晶型CSVII原料药在40℃/75％相对湿度条件下放置至少3个月晶型未发生变化，在60℃/75％相对湿度条件下至少2个月晶型未发生变化，且化学纯度均在99.9％以上，储存过程中纯度基本保持不变。说明晶型CSVII原料药在加速条件及更严苛的条件下，具有较好的稳定性。原料药在加速条件及更严苛的条件下的稳定性对于药物至关重要。原料药在储存、运输、生产过程中会遇到季节差异、不同地区气候差异和天气因素等带来的高温和高湿条件。晶型CSVII原料药在苛刻的条件下具有较好的稳定性，有利于避免偏离标签上的贮藏条件对药物质量的影响。
晶型的转变会导致药物的吸收发生变化，影响生物利用度，甚至引起药物的毒副作用。良好的化学稳定性可以确保在储存过程中基本没有杂质产生。晶型CSVII具有良好的物理化学稳定性，保证原料药和制剂质量一致可控，最大程度地减少药物由于晶型改变或杂质产生引起的药物质量变化，生物利用度改变，甚至引起药物的毒副作用。
进一步地，本发明提供的晶型CSVII还具有以下有益效果：
(1)与现有技术相比，本发明提供的晶型CSVII具有更优的可压性。晶型CSVII良好的可压性可以有效改善压片工艺中的硬度/脆碎度不合格、裂片等问题，使制剂工艺更为可靠，改善产品外观，提升产品质量。更优的可压性亦可提升压片速度进而提升生产效率，同时可 减少用于改善可压性的辅料的成本支出。
(2)与现有技术相比，本发明晶型CSVII具有更优的黏附性。黏附性评价结果表明，晶型CSVII的吸附量低于现有技术晶型的吸附量。晶型CSVII更优的黏附性可有效改善或者避免干法制粒和片剂压片等环节引起的黏轮、黏冲等现象，有利于改善产品外观、重量差异等。此外，晶型CSVII更优的黏附性还能有效减少原料的团聚现象，减少物料和器具之间的吸附，利于原料的分散及与其他辅料的混合，增加物料混合时的混合均匀度及最终产品的含量均匀度。
根据本发明的目的，本发明还提供一种药物组合物，所述药物组合物包含有效治疗量的晶型CSV、晶型CSVI、晶型CSVII及药学上可接受的载体或辅料。
进一步地，本发明提供晶型CSV、晶型CSVI、晶型CSVII在制备治疗转甲状腺素蛋白淀粉样病变引发的疾病的药物中的用途。
更进一步地，本发明提供晶型CSV、晶型CSVI、晶型CSVII在制备治疗转甲状腺素素蛋白家族性淀粉样多发性神经病变和/或转甲状腺素素蛋白心肌病的药物中的用途。
本发明中，所述“搅拌”，采用本领域的常规方法完成，例如磁力搅拌或机械搅拌，搅拌速度为50-1800转/分钟，其中，磁力搅拌优选为300-900转/分钟，机械搅拌优选为100-300转/分钟。
所述“分离”，采用本领域的常规方法完成，例如离心或过滤。“离心”的操作为：将欲分离的样品置于离心管中，以10000转/分的速率进行离心，至固体全部沉至离心管底部。
所述“干燥”可以在室温或更高的温度下进行。干燥温度为室温到约60℃，或者到50℃，或者到40℃。干燥时间可以为2-48小时，或者过夜。干燥在通风橱、鼓风烘箱或真空烘箱里进行。
本发明中，“晶体”或“多晶型”指被X射线粉末衍射表征证实的固体。本领域技术人员能够理解，这里所讨论的理化性质可以被表征，其中的实验误差取决于仪器的条件、样品的准备和样品的纯度。特别是，本领域技术人员公知，X射线粉末衍射图通常会随着仪器条件的不同而有所改变。特别需要指出的是，X射线粉末衍射图中衍射峰的相对强度也可能随着实验条件的变化而变化，所以衍射峰强度的顺序不能作为唯一或决定性因素。事实上，X射线粉末衍射图中衍射峰的相对强度与晶体的择优取向有关，本发明所示的衍射峰强度为说明性而非用于绝对比较。另外，衍射峰位置的实验误差通常在5％或更少，这些位置的误差也应该被考虑进去，通常允许有±0.2°的误差。另外，由于样品厚度等实验因素的影响，会造成衍射峰角度的整体偏移，通常允许一定的偏移。因而，本领域技术人员可以理解的是，本发明中一个晶型的X射线粉末衍射图不必和这里所指的实施例中的X射线粉末衍射图完全一致，任何具有和这些图谱中的特征峰相同或相似的X射线粉末衍射图的晶型均属于本发明的范畴之内。本领域技术人员能够将本发明所列的X射线粉末衍射图和一个未知晶型的X射线粉末衍射图相比较，以证实这两组图反映的是相同还是不同的晶型。
在一些实施方案中，本发明的晶型CSV、晶型CSVI、晶型CSVII是纯的，基本没有混合任何其他晶型。本发明中，“基本没有”当用来指新晶型时指这个晶型含有少于20％(重量)的其他晶型，尤其指少于10％(重量)的其他晶型，更指少于5％(重量)的其他晶型，更指少于1％(重量)的其他晶型。
本发明中术语“约”，当用来指可测量的数值时，例如质量、时间、温度等，意味着可围绕具体数值有一定的浮动的范围，该范围可以为±10％、±5％、±1％、±0.5％、或±0.1％。
附图说明
图1为根据实施例1所得晶型CSV的XRPD图
图2为根据实施例1所得晶型CSV的TGA图
图3为根据实施例1所得晶型CSV的 1H NMR图
图4为根据实施例2所得晶型CSV的XRPD图
图5为根据实施例3所得晶型CSV的XRPD图
图6为根据实施例4所得晶型CSV的DSC图
图7为晶型CSV在不同条件下放置前后的XRPD对比图(从上至下依次为：在60℃/75％相对湿度开口放置2个月，在60℃/75％相对湿度闭口放置2个月，在40℃/75％相对湿度开口放置6个月，在40℃/75％相对湿度闭口放置6个月，在25℃/60％相对湿度开口放置6个月，放置前)
图8为晶型CSV研磨前后的XRPD对比图(从上至下依次为：研磨后、研磨前)
图9为WO2016038500晶型1研磨前后的XRPD对比图(从上至下依次为：研磨后、研磨前)
图10为晶型CSV的DVS图
图11为晶型CSV在DVS测试前后的XRPD对比图(从上至下依次为：DVS测试前、DVS测试后)
图12为晶型CSV在制剂前后的XRPD对比图(从上至下依次为：制剂、晶型CSV)
图13为晶型CSV制剂稳定性的XRPD对比图(从上至下依次为：在25℃/60％相对湿度双铝泡罩放置3个月，在40℃/75％相对湿度双铝泡罩放置3个月后、放置前)
图14为晶型CSV制剂和WO2016038500晶型1制剂在pH6.8磷酸盐缓冲盐溶液中的溶出度曲线
图15为根据实施例13所得晶型CSVI的XRPD图
图16为根据实施例14所得晶型CSVI的XRPD图
图17为根据实施例14所得晶型CSVI的TGA图
图18为根据实施例14所得晶型CSV的DSC图
图19为根据实施例14所得晶型CSVI的 1H NMR图
图20为晶型CSVI在不同条件下放置前后的XRPD对比图(从上至下依次为：在60℃/75％相对湿度闭口放置2个月，在40℃/75％相对湿度开口放置6个月，在40℃/75％相对湿度闭口放置6个月，在25℃/60％相对湿度开口放置6个月，放置前)
图21为晶型CSVI的DVS图
图22为晶型CSVI在DVS测试前后的XRPD对比图(从上至下依次为：DVS测试前、DVS测试后)
图23为晶型CSVI制剂和WO2016038500晶型1制剂在pH 6.8的磷酸盐缓冲盐溶液(PBS)+1％吐温80中的溶出度曲线
图24为晶型CSVI制剂和WO2016038500晶型1制剂在pH 6.8的磷酸盐缓冲盐溶液(PBS)+3％吐温80中的溶出度曲线
图25为根据实施例19所得晶型CSVII的XRPD图
图26为根据实施例19所得晶型CSVII的TGA图
图27为根据实施例19所得晶型CSVII的DSC图
图28为根据实施例19所得晶型CSVII的 1H NMR图
图29为晶型CSVII在不同条件下放置前后的XRPD对比图(从上至下依次为：在60℃/75％相对湿度闭口放置2个月，在40℃/75％相对湿度开口放置3个月，在40℃/75％相对湿度闭口放置3个月，在25℃/60％相对湿度开口放置3个月，放置前)
图30为晶型CSVII的DVS图
图31为晶型CSVII在DVS测试前后的XRPD对比图(从上至下依次为：DVS测试前、DVS测试后)
图32为晶型CSVII制剂和WO2016038500晶型1制剂在pH 6.8的磷酸盐缓冲盐溶液(PBS)+1％吐温80中的溶出度曲线
具体实施方式
结合以下实施例对本发明做详细说明，所述实施例详细描述本发明的晶型的制备和使用方法。对本领域技术人员显而易见的是，对于材料和方法两者的许多改变可在不脱离本发明范围的情况下实施。
本发明中所用到的缩写的解释如下：
XRPD：X射线粉末衍射
DSC：差示扫描量热分析
TGA：热重分析
DVS：动态水分吸附
1H NMR：液态核磁氢谱
UPLC：超高效液相色谱
采集数据所用的仪器及方法：
本发明所述的除制剂稳定性以外样品的X射线粉末衍射图在Bruker D2 PHASER X射线粉末衍射仪上采集。所述X射线粉末衍射的方法参数如下：
X射线光源：Cu,Kα
Kα1
Figure PCTCN2020128376-appb-000002
：1.54060；Kα2
Figure PCTCN2020128376-appb-000003
：1.54439
Kα2/Kα1强度比例：0.50
本发明所述的制剂稳定性的X射线粉末衍射图在Bruker D8 Discover X射线粉末衍射仪上采集。本发明所述的X射线粉末衍射的方法参数如下：
X射线光源：Cu,Kα
Kα1
Figure PCTCN2020128376-appb-000004
：1.54056；Kα2
Figure PCTCN2020128376-appb-000005
：1.54439
Kα2/Kα1强度比例：0.50
电压：40仟伏特(kV)
电流：40毫安培(mA)
扫描范围：自4.0至40.0度
本发明所述的差示扫描量热分析(DSC)图在TA Q2000上采集。所述的DSC的方法参数如下：
扫描速率：10℃/min
保护气体：氮气
本发明所述的热重分析(TGA)图在TA Q500上采集。所述的TGA的方法参数如下：
扫描速率：10℃/min
保护气体：氮气
本发明所述动态水分吸附(DVS)图在由SMS公司(Surface Measurement Systems Ltd.)生产的Intrinsic动态水分吸附仪上采集。仪器控制软件是DVS-Intrinsic control software。所述的动态水分吸附仪的方法参数如下：
温度：25℃
载气，流速：N 2,200毫升/分钟
单位时间质量变化：0.002％/分钟
相对湿度范围：0％RH-95％RH
核磁共振氢谱数据( 1H NMR)采自于Bruker Avance II DMX 400M Hz核磁共振波谱仪。称量1-5mg样品，用0.5mL氘代二甲亚砜溶解，配成2-10mg/mL的溶液。
本发明中的动态溶解度测试参数表1。
表1
Figure PCTCN2020128376-appb-000006
Figure PCTCN2020128376-appb-000007
本发明中纯度检测方法如表2。
表2
Figure PCTCN2020128376-appb-000008
本发明中制剂溶出度检测方法如表3。
表3
Figure PCTCN2020128376-appb-000009
Figure PCTCN2020128376-appb-000010
除非特殊说明，以下实施例均在室温条件下操作。所述“室温”不是特定的温度值，是指10-30℃温度范围。
根据本发明，作为原料的所述化合物I包括但不限于固体形式(结晶或无定形)、油状、液体形式和溶液。优选地，作为原料的化合物I为固体形式。
以下实施例中所使用的化合物I可根据现有技术制备得到，例如根据WO2016038500专利申请所记载的方法制备获得。
具体实施方式
实施例1晶型CSV的制备方法
称取252.6mg富马酸于玻璃小瓶中，加入18.0mL丙酮溶剂和312.0mg他发米帝司游离酸，室温下悬浮搅拌约5天，分离得到固体并在25℃下真空干燥约1小时。称取268.8mg干燥后的样品于玻璃小瓶中，加入5.0mL水后室温下搅拌约1小时，再次加入4.0mL水继续搅拌过夜，分离并在50℃下真空干燥得到结晶固体。经检测，所得结晶固体为本发明晶型CSV，其XRPD图如图1，XRPD数据如表4所示。
晶型CSV的TGA如图2所示，将其加热至150℃时，具有约0.2％的质量损失，从150℃加热到225℃，具有16.2％的质量损失，对应富马酸的脱去。
晶型CSV的 1H NMR图如图3所示，出峰结果与化合物I结构吻合，其中化学位移在6.63处的共振峰为富马酸的特征峰。核磁结果显示晶型CSV中化合物I和富马酸的摩尔比为1:0.5。，具体核磁数据为： 1H NMR(400MHz,DMSO)δ13.21(s,2H),8.29(d,J＝1.0Hz,1H),8.17(d,J＝1.9Hz,2H),8.05(dd,J＝8.4,1.5Hz,1H),7.97(t,J＝1.9Hz,1H),7.94(d,J＝8.3Hz,1H),6.63(s,1H).
表4
衍射角2θ d值 强度％
5.16 17.11 3.17
7.54 11.73 1.27
8.74 10.11 2.46
9.55 9.26 16.17
10.35 8.54 4.80
13.39 6.61 100.00
15.55 5.70 13.79
16.47 5.38 18.61
17.58 5.04 1.91
17.95 4.94 25.21
19.17 4.63 13.94
20.78 4.27 48.53
21.50 4.13 1.54
22.82 3.90 61.97
23.88 3.73 14.37
24.20 3.68 11.14
24.68 3.61 5.59
25.98 3.43 5.70
26.24 3.40 7.05
26.63 3.35 10.57
27.07 3.29 7.40
27.88 3.20 5.01
28.96 3.08 4.80
30.56 2.93 4.01
31.50 2.84 10.61
32.51 2.75 5.58
33.08 2.71 15.03
35.79 2.51 14.59
36.35 2.47 9.47
36.55 2.46 7.21
37.33 2.41 3.35
38.37 2.35 3.82
39.33 2.29 6.84
实施例2晶型CSV的制备方法
称取14.1mg他发米帝司游离酸和12.0mg富马酸于玻璃小瓶中，加入1.0mL丙酮溶剂，室温下悬浮搅拌约7天，分离得到结晶固体。
经检测，所得结晶固体为本发明晶型CSV，其X射线粉末衍射结果如图4，表5所示。
表5
衍射角2θ d值 强度％
5.14 17.18 2.35
9.56 9.25 15.03
10.38 8.52 3.25
13.40 6.61 100.00
15.57 5.69 9.66
16.48 5.38 15.15
17.96 4.94 28.85
19.18 4.63 12.90
20.80 4.27 33.22
22.83 3.90 57.30
23.89 3.72 10.53
24.22 3.67 6.89
24.66 3.61 3.08
26.00 3.43 3.99
26.25 3.40 6.04
26.65 3.35 7.52
27.09 3.29 5.32
27.90 3.20 3.22
28.94 3.09 2.80
30.55 2.93 2.09
31.51 2.84 8.58
32.50 2.76 4.18
33.08 2.71 11.75
35.80 2.51 12.00
36.36 2.47 7.84
36.57 2.46 5.93
38.40 2.34 2.12
39.34 2.29 4.63
实施例3晶型CSV的制备方法
将5.02g他发米帝司游离酸、1.88g富马酸和约250mL正丁醇/苯甲醚(1:4,v/v)溶剂加入反应釜中，并用搅拌桨搅拌，加热至约100℃时，固体溶清，降温至85℃后加入约10.0mg晶型CSV晶种，熟化约15分钟，降温至5℃，过滤悬浊液，湿滤饼在50℃真空干燥，即得到结晶固体。经检测，所得结晶固体为本发明晶型CSV，其XRPD图如图5所示，XRPD数据如表6所示。
表6
衍射角2θ d值 强度％
7.56 11.69 4.89
9.59 9.23 57.47
13.40 6.61 97.83
15.58 5.69 4.44
16.48 5.38 100.00
17.96 4.94 12.03
19.18 4.63 47.28
20.78 4.27 5.87
22.80 3.90 61.95
23.89 3.72 56.64
26.00 3.43 21.18
28.98 3.08 6.69
30.58 2.92 2.05
31.51 2.84 20.40
32.56 2.75 7.48
33.32 2.69 20.99
35.78 2.51 47.09
36.58 2.46 7.70
39.31 2.29 15.47
实施例4晶型CSV的制备方法
将30.00g他发米帝司游离酸、11.63g富马酸和约1350mL正丁醇/苯甲醚(1:3,v/v)溶剂加入2L反应釜中，并用搅拌桨搅拌，加热至95℃溶清固体，降温至85℃后加入600.8mg晶型CSV晶种，熟化约1小时，用两个小时降温至5℃，过滤悬浊液，湿滤饼经正庚烷洗涤后放到50℃真空干燥，即得到结晶固体。经检测，所得结晶固体为本发明晶型CSV。
DSC如图6所示，加热至265.2℃开始出现吸热信号。
实施例5晶型CSV的制备方法
将0.51g他发米帝司游离酸、0.94g富马酸和15mL四氢呋喃溶剂加入50mL反应釜中，并用搅拌桨搅拌，加热至60℃固体溶清，降温至50℃后加入5.3mg晶型CSV晶种，熟化约5分钟，降温至25℃即得到结晶固体。经检测，所得结晶固体为本发明晶型CSV。
实施例6晶型CSV动态溶解度
进行药物溶解度测试以预测药物体内性能的时候，很重要的一点是尽可能的模拟体内条件。对口服药，用SGF(模拟胃液)、FaSSIF(模拟禁食状态肠液)、FeSSIF(模拟进食状态肠液)可以模拟体内条件并预测进食的影响。在此类介质中测试的溶解度与人体环境中的溶解度更加接近。
取本发明的晶型CSV和WO2016038500晶型1各20mg，分别分散在3.0mL的SGF、3.0mL的FaSSIF和3.0mL的FeSSIF中配制成饱和溶液，平衡1小时后，用超高效液相色谱测试饱和溶液中化合物I的含量(μg/mL)，结果如表7所示。
表7
介质 晶型CSV WO2016038500晶型1
SGF 5.6 1.5
FeSSIF 6.0 0.6
FaSSIF 11.5 9.0
结果表明，晶型CSV相较于WO2016038500晶型1在SGF、FeSSIF和FaSSIF中均具有更高的溶解度，特别是在FeSSIF中，溶解度是WO2016038500晶型1的10倍。
实施例7晶型CSV的稳定性
称取5份5mg的本发明晶型CSV，分别在25℃/60％RH、40℃/75％RH、60℃/75％RH条件下放置一定时间，采用HPLC和XRPD法测定纯度与晶型，结果如表8所示，XRPD对比图如图7所示。
表8
Figure PCTCN2020128376-appb-000011
结果表明，晶型CSV在25℃/60％RH和40℃/75％RH条件下至少可稳定6个月，可见，晶型CSV在长期和加速条件下均可保持良好的稳定性。60℃/75％RH条件下放置至少可稳定2个月，可见在更严苛的条件下晶型CSV也有较好的稳定性。
实施例8晶型CSV的研磨稳定性
分别将本发明晶型CSV及WO2016038500晶型1置于研钵中，手动研磨5分钟，研磨前后进行XRPD测试，测试结果如图8和图9所示。
结果表明，本发明晶型CSV经过研磨后结晶度基本保持不变，而WO2016038500晶型1经过研磨后结晶度有所下降。相比于WO2016038500晶型1，晶型CSV具有更好的机械稳定性。
实施例9晶型CSV的可压性
采用ENERPAC手动压片机进行压片，压片时，选择Φ6mm圆形平冲，分别加入80mg晶型CSV、WO2016038500晶型1，采用10kN的压力压制成圆形片剂，室温放置24h，待完全弹性复原后，采用游标卡尺测量片剂的直径(D)和厚度(L)，采用片剂硬度测定仪测试其径向破碎力(硬度，H)，利用公式T＝2H/πDL*9.8计算粉体的抗张强度。在一定的压力下，抗张强度越大的，表示其可压性越好。结果如表9所示。
表9
晶型 厚度(mm) 直径(mm) 硬度(kgf) 抗张强度(MPa)
WO2016038500晶型1 1.35 6.02 2.32 1.78
晶型CSV 1.76 6.01 4.85 2.86
结果表明，相比WO2016038500晶型1，晶型CSV具有更优的可压性。
实施例10晶型CSV的引湿性
称取本发明晶型CSV约10mg，采用动态水分吸附(DVS)仪测试其引湿性，在0-95％-0相对湿度下循环一次，记录每个湿度下的质量变化，并且在DVS测试前后进行XRPD测试。 晶型CSV的DVS图如图10所示，引湿性测定前后的XRPD如图11所示，晶型CSV在80％RH条件下引湿性增重为0.09％，属于无或几乎无引湿性。
关于引湿性特征描述与引湿性增重的界定(中国药典2015年版通则9103药物引湿性试验指导原则，实验条件：25℃±1℃，80％相对湿度，欧洲药典第九版5.11中对引湿性的界定与中国药典一致)：
潮解：吸收足量水分形成液体
极具引湿性：引湿增重不小于15.0％
有引湿性：引湿增重小于15.0％但不小于2.0％
略有引湿性：引湿增重小于2.0％但不小于0.2％
无或几乎无引湿性：引湿增重小于0.2％
实施例11晶型CSV制剂的稳定性
将本发明制得的晶型CSV采用表10、表11所述制剂处方和工艺制成制剂，并测试晶型CSV制剂前后的XRPD，XRPD对比图如图12所示。结果表明，晶型CSV在制剂处方工艺前后晶型保持稳定。
表10
Figure PCTCN2020128376-appb-000012
表11
Figure PCTCN2020128376-appb-000013
Figure PCTCN2020128376-appb-000014
测试该制剂的稳定性，结果如表12所示，XRPD对比图如图13所示。结果表明，晶型CSV制剂在25℃/60％RH和40℃/75％RH条件下至少可以稳定3个月。
表12
放置条件 放置时间 晶型 纯度％
起始制剂样品 —— 晶型CSV 99.84
25℃/60％RH 3个月 晶型CSV 99.87
40℃/75％RH 3个月 晶型CSV 99.86
实施例12晶型CSV制剂的体外溶出度
将本发明制得的晶型CSV和WO2016038500晶型1采用表13和表14所述制剂处方和工艺制成固体胶囊，并在pH 6.8的磷酸盐缓冲盐溶液(PBS)中测试不同时间的累计溶出度，测试参数如表15所示，测试结果见表16和图14。
表13
Figure PCTCN2020128376-appb-000015
表14
Figure PCTCN2020128376-appb-000016
Figure PCTCN2020128376-appb-000017
表15
溶出仪 Sotax AT7
方法 桨法
规格 61mg
介质体积 900mL
转速 50rpm
介质温度 37℃
取样点 pH 6.8 PBS：5，10，15，20，30，45，60min
补充介质 No
表16
Figure PCTCN2020128376-appb-000018
晶型CSV的累积溶出度在pH6.8磷酸盐缓冲盐溶液中高于WO2016038500晶型1，相较WO2016038500晶型1，本发明晶型CSV具有更优的生物利用度。
实施例13晶型CSVI的制备方法
称取15.4mg他发米帝司游离酸和19.3mg戊二酸于1.5mL玻璃小瓶中，加入1.0mL乙酸乙酯溶剂，室温下悬浮搅拌约7天，分离得到结晶固体。
经检测，所得结晶固体为本发明晶型CSVI，其X射线粉末衍射图如图15，X射线粉末衍射数据如表17所示。
表17
衍射角2θ d值 强度％
9.98 8.87 10.74
11.21 7.89 2.94
14.11 6.28 100.00
16.85 5.26 1.27
17.20 5.15 13.63
19.05 4.66 58.71
22.53 3.95 5.72
24.01 3.71 3.86
24.34 3.66 10.38
25.15 3.54 1.77
26.60 3.35 2.18
33.39 2.68 4.32
34.08 2.63 4.59
34.80 2.58 1.48
35.49 2.53 3.67
实施例14晶型CSVI的制备方法
称取454.3mg他发米帝司游离酸和597.7mg戊二酸于20mL玻璃小瓶中，加入10.0mL乙酸乙酯溶剂，室温下悬浮搅拌约6天，分离得到固体并在30℃下真空干燥约2.5小时。将固体置于10.0mL乙酸乙酯溶剂中并在室温下悬浮搅拌约2天，再次加入134.4mg戊二酸继续搅拌约4天，分离得到固体并在25℃下真空干燥过夜。将固体置于10.0mL正庚烷溶剂中在室温下悬浮搅拌约2小时，分离得到固体并在25℃下真空干燥过夜。将固体置于20.0mL正庚烷溶剂中并在室温下悬浮搅拌约1天，分离得到固体并在25℃下真空干燥过夜。称取20.5mg干燥固体于1.5mL玻璃小瓶中，加入1.0mL正庚烷/乙酸乙酯(4:1,v/v)溶剂并在室温下搅拌过夜，分离得到结晶固体。
经检测，所得结晶固体为本发明晶型CSVI，其X射线粉末衍射图如图16，X射线粉末衍射数据如表18所示。
晶型CSVI的TGA图如图17所示，将其加热至200℃时，具有约17.5％的质量损失，对应戊二酸的脱去。
晶型CSVI的DSC图如图18所示，将其加热至166.6℃时，开始出现吸热峰。
晶型CSVI的 1H NMR图如图19所示，结果与化合物I结构吻合，其中化学位移在2.23和1.69处的共振峰为戊二酸的特征峰。核磁结果显示晶型CSVI中他发米帝司和戊二酸的摩尔比为1:0.5。具体核磁数据为： 1H NMR(400MHz,DMSO)δ8.29(d,J＝0.9Hz,1H),8.18(d,J＝1.9Hz,2H),8.05(dd,J＝8.4,1.4Hz,1H),7.97(t,J＝1.9Hz,1H),7.94(d,J＝8.3Hz,1H),2.23(t,J＝7.4Hz,2H),1.69(p,J＝7.4Hz,1H)。
表18
衍射角2θ d值 强度％
9.98 8.86 10.57
11.21 7.90 2.35
14.11 6.28 100.00
16.85 5.26 1.10
17.20 5.16 11.98
19.05 4.66 60.47
22.53 3.95 5.47
24.01 3.71 3.05
24.34 3.66 10.77
25.14 3.54 1.84
26.60 3.35 2.23
33.38 2.68 4.13
34.07 2.63 4.15
34.78 2.58 1.20
35.47 2.53 2.97
实施例15晶型CSVI动态溶解度
进行药物溶解度测试以预测药物体内性能的时候，很重要的一点是尽可能的模拟体内条件。使测试的溶解度与人体环境中的溶解度更加接近。
取本发明的晶型CSVI和WO2016038500晶型1各20mg，分别分散在3.0mL的SGF、中配制成饱和溶液，平衡1小时后，用超高效液相色谱测试饱和溶液中化合物I的含量(μg/mL)，结果如表19所示。
表19
介质 晶型CSVI WO2016038500晶型1
SGF 2.4 1.5
结果表明，晶型CSVI相较于WO2016038500晶型1在SGF水中具有更高的溶解度。
实施例16晶型CSVI的稳定性
称取4份5mg的本发明晶型CSVI，分别放置在25℃/60％RH、40℃/75％RH、60℃/75％RH条件下，采用HPLC和XRPD法测定纯度与晶型。结果如表20所示，XRPD对比图如图20所示。
表20
Figure PCTCN2020128376-appb-000019
结果表明，晶型CSVI在25℃/60％RH和40℃/75％RH条件下至少可稳定6个月，可见，晶型CSVI在长期和加速条件下均可保持良好的稳定性。60℃/75％RH条件下放置至少可稳定2个月，可见在更严苛的条件下晶型CSVI稳定性也很好。
实施例17晶型CSVI的引湿性
称取本发明晶型CSVI约10mg，采用动态水分吸附(DVS)仪测试其引湿性，在0-95％-0 相对湿度下循环一次，记录每个湿度下的质量变化，并且在DVS测试前后进行XRPD测试。晶型CSVI的DVS图如图21所示，引湿性测定前后的XRPD如图22所示，晶型CSVI在80％RH条件下引湿性增重为0.21％，属于略有引湿性。
实施例18晶型CSVI制剂的体外溶出度
将本发明晶型CSVI和WO2016038500晶型1采用表21所述制剂处方和工艺制成固体片剂，并在pH 6.8的磷酸盐缓冲盐溶液(PBS)+1％吐温80及pH 6.8的磷酸盐缓冲盐溶液(PBS)+3％吐温80中测试不同时间的累计溶出度，测试参数如表22和表23所示，测试结果见表24(图23)和表25(图24)。
表21
Figure PCTCN2020128376-appb-000020
表22
Figure PCTCN2020128376-appb-000021
表23
Figure PCTCN2020128376-appb-000022
Figure PCTCN2020128376-appb-000023
表24
Figure PCTCN2020128376-appb-000024
表25
Figure PCTCN2020128376-appb-000025
晶型CSVI的累积溶出度在pH6.8PBS+1％吐温80和pH6.8PBS+3％吐温80中的溶出度均高于WO2016038500晶型1，相较WO2016038500晶型1，本发明晶型CSVI具有更优的 生物利用度。
实施例19晶型CSVII的制备方法
称取308.9mg他发米帝司游离酸和145.9mg己二酸于20mL玻璃小瓶中，加入15mL乙酸乙酯溶剂，50℃下悬浮搅拌约5天后加入72.9mg己二酸，50℃下悬浮搅拌约2天后加入29.1mg己二酸，50℃下悬浮搅拌约6天后抽滤，25℃下鼓风干燥约4.5小时后得到固体。将固体置于10mL丙酮/正庚烷(1:4,v/v)溶剂中并室温下悬浮搅拌过夜后抽滤，30℃下真空干燥过夜，得到结晶固体。
经检测，所得结晶固体为本发明所述之晶型CSVII，其X射线粉末衍射数据如表26所示，XRPD图如图25所示。
TGA图如图26所示，将其加热至200℃时，具有约19.0％的质量损失，对应己二酸的脱去。
DSC图如图27所示，将其加热至166.7℃时，开始出现吸热峰。
1H NMR如图28所示，出峰结果与化合物I结构吻合，其中2.21与1.55-1.44处的共振峰为己二酸的特征峰。核磁结果显示晶型CSVII中化合物I和己二酸的摩尔比为1:0.5，具体核磁数据为： 1H NMR(400MHz,DMSO)δ8.30(d,J＝0.8Hz,1H),8.19(d,J＝1.9Hz,2H),8.05(dd,J＝8.4,1.4Hz,1H),7.98(t,J＝1.9Hz,1H),7.95(d,J＝8.4Hz,1H),2.21(t,J＝6.5Hz,2H),1.55–1.44(m,2H).
表26
衍射角2θ d值 强度％
5.61 15.77 1.51
9.84 8.99 5.11
11.27 7.85 8.33
13.86 6.39 100.00
16.95 5.23 4.56
17.20 5.15 6.48
18.77 4.73 49.82
19.79 4.49 1.40
22.67 3.92 7.21
24.07 3.70 12.72
24.55 3.63 1.53
25.61 3.48 13.83
27.03 3.30 2.78
28.13 3.17 2.01
29.12 3.07 1.45
29.59 3.02 2.10
32.84 2.73 1.51
33.51 2.67 3.98
35.25 2.55 3.66
实施例20晶型CSVII动态溶解度
取本发明的晶型CSVII和WO2016038500晶型1各20mg，分别分散在3.0mL的SGF、3.0mL的FaSSIF和3.0mL的FeSSIF中配制成饱和溶液，平衡1小时后，用超高效液相色谱测试饱和溶液中化合物I的含量(μg/mL)，结果如表27所示。
表27
介质 晶型CSVII WO2016038500晶型1
SGF 19.4 1.5
FeSSIF 1.3 0.6
FaSSIF 13.3 9.0
结果表明，晶型CSVII相较于WO2016038500晶型1在SGF、FeSSIF和FaSSIF中均具有更高的溶解度，特别是在SGF中，溶解度是WO2016038500晶型1的12倍多。
实施例21晶型CSVII的稳定性
称取4份5mg的本发明晶型CSVII，分别放置在25℃/60％RH、40℃/75％RH、60℃/75％RH条件下，采用HPLC和XRPD法测定纯度与晶型。结果如表28所示，XRPD对比图如图29所示。
表28
Figure PCTCN2020128376-appb-000026
结果表明，晶型CSVII在25℃/60％RH和40℃/75％RH条件下至少可稳定3个月，可见，晶型CSVII在长期和加速条件下均可保持良好的稳定性。60℃/75％RH条件下放置至少可稳定2个月，可见在更严苛的条件下晶型CSVII稳定性也很好。
实施例22晶型CSVII的可压性
采用ENERPAC手动压片机进行压片，压片时，选择Φ6mm圆形平冲，分别加入80mg晶型CSVII、WO2016038500晶型1，采用10kN的压力压制成圆形片剂，室温放置24h，待完全弹性复原后采用游标卡尺测量片剂的直径(D)和厚度(L)，采用片剂硬度测定仪测试其径向破碎力(硬度，H)，利用公式T＝2H/πDL*9.8计算粉体的抗张强度。在一定的压力下，抗张强度越大的，表示其可压性越好。结果如下表29所示。
表29
晶型 厚度(mm) 直径(mm) 硬度(kgf) 抗张强度(MPa)
WO2016038500晶型1 1.35 6.02 2.32 1.78
晶型CSVII 1.93 6.00 7.45 4.02
结果表明，相比WO2016038500晶型1，晶型CSVII具有更优的可压性。
实施例23晶型CSVII的引湿性
称取本发明晶型CSVII约10mg，采用动态水分吸附(DVS)仪测试其引湿性，在0-95％-0相对湿度下循环一次，记录每个湿度下的质量变化，并且在DVS测试前后进行XRPD测试。晶型CSVII的DVS图如图30所示，引湿性测定前后的XRPD如图31所示，晶型CSVII在80％RH条件下引湿性增重为0.04％，属于无或几乎无引湿性。
实施例24晶型CSVII的黏附性
分别将约30mg晶型CSVII和WO2016038500晶型1加入到8mm圆形平冲中，采用10kN的压力进行压片处理，压片后停留约半分钟，称量冲头吸附的粉末量。采用该方法连续压制两次后，记录冲头累计的平均黏附量。具体的实验结果见表30。
表30
晶型 平均黏附量(mg)
WO2016038500晶型1 0.265
晶型CSVII 0.200
结果表明，晶型CSVII的黏附性优于现有技术晶型。
实施例25晶型CSVII制剂的体外溶出度
将本发明制得的晶型CSVII和WO2016038500晶型1采用表31所述制剂处方和工艺制成固体片剂，并在pH 6.8的磷酸盐缓冲盐溶液(PBS)+1％吐温80中测试不同时间的累计溶出度，测试参数如表32所示，测试结果见表33和图32。
表31
Figure PCTCN2020128376-appb-000027
表32
Figure PCTCN2020128376-appb-000028
Figure PCTCN2020128376-appb-000029
表33
Figure PCTCN2020128376-appb-000030
晶型CSVII的累积溶出度在pH6.8PBS+1％吐温80中高于WO2016038500晶型1，相较WO2016038500晶型1，本发明晶型CSVI具有更优的生物利用度。
对比例1WO2019175263化合物I晶型制剂的稳定性
将WO2019175263化合物I晶型采用表34、表35所述制剂处方和工艺制成制剂，并测试该晶型制剂前后的XRPD。结果表明，该晶型在制剂工艺前后不稳定，在室温搅拌过程中发生转晶。
表34
Figure PCTCN2020128376-appb-000031
Figure PCTCN2020128376-appb-000032
表35
Figure PCTCN2020128376-appb-000033
上述实施例只为说明本发明的技术构思及特点，其目的在于让熟悉此项技术的人士能够了解本发明的内容并据以实施，并不能以此限制本发明的保护范围。凡根据本发明精神实质所作的等效变化或修饰，都应涵盖在本发明的保护范围之内。

Claims (19)

  1. 一种他发米帝司的晶型CSV，其特征在于，晶型CSV为他发米帝司富马酸共晶。
  2. 根据权利要求1所述的晶型CSV，其特征在于，使用Cu-Kα辐射，其X射线粉末衍射图在2θ值为13.4°±0.2°、22.8°±0.2°、20.8°±0.2°处具有特征峰。
  3. 根据权利要求1所述的晶型CSV，其特征在于，使用Cu-Kα辐射，其X射线粉末衍射图在2θ值为18.0°±0.2°、16.5°±0.2°、9.6°±0.2°中的1处或2处或3处具有特征峰。
  4. 根据权利要求1所述的晶型CSV，其特征在于，使用Cu-Kα辐射，其X射线粉末衍射图在2θ值为15.6°±0.2°、19.2°±0.2°、23.9°±0.2°中的1处或2处或3处具有特征峰。
  5. 根据权利要求1所述的晶型CSV，其特征在于，晶型CSV为无水晶型。
  6. 一种权利要求1所述的晶型CSV的制备方法，其特征在于，将他发米帝司游离酸与富马酸置于酮类、酯类、醚类或醇类与醚类的混合溶剂中搅拌获得晶型CSV。
  7. 一种他发米帝司的晶型CSVI，其特征在于，晶型CSVI为他发米帝司戊二酸共晶。
  8. 根据权利要求7所述的晶型CSVI，其特征在于，使用Cu-Kα辐射，其X射线粉末衍射图在2θ值为14.1°±0.2°、19.1°±0.2°、17.2°±0.2°处具有特征峰。
  9. 根据权利要求7所述的晶型CSVI，其特征在于，使用Cu-Kα辐射，其X射线粉末衍射图在2θ值为10.0°±0.2°、22.5°±0.2°、24.3°±0.2°中的1处或2处或3处具有特征峰。
  10. 根据权利要求7所述的晶型CSVI，其特征在于，使用Cu-Kα辐射，其X射线粉末衍射图在2θ值为34.1°±0.2°、33.4°±0.2°、11.2°±0.2°、35.5°±0.2°中的1处或2处或3处或4处具有特征峰。
  11. 一种权利要求7所述的晶型CSVI的制备方法，其特征在于，将他发米帝司游离酸与戊二酸置于酯类溶剂中搅拌获得晶型CSVI。
  12. 一种他发米帝司的晶型CSVII，其特征在于，晶型CSVII为他发米帝司己二酸共晶。
  13. 根据权利要求12所述的晶型CSVII，其特征在于，使用Cu-Kα辐射，其X射线粉末衍射图在2θ值为13.9°±0.2°、18.8°±0.2°、25.6°±0.2°处具有特征峰。
  14. 根据权利要求12所述的晶型CSVII，其特征在于，使用Cu-Kα辐射，其X射线粉末衍射图在2θ值为24.1°±0.2°、11.3°±0.2°、22.7°±0.2°中的1处或2处或3处具有特征峰。
  15. 根据权利要求12所述的晶型CSVII，其特征在于，使用Cu-Kα辐射，其X射线粉末衍射图在2θ值为17.2°±0.2°、9.8°±0.2°、17.0°±0.2°中的1处或2处或3处具有特征峰。
  16. 一种权利要求12所述的晶型CSVII的制备方法，其特征在于，将他发米帝司游离酸与己二酸置于酯类溶剂中搅拌获得晶型CSVII。
  17. 一种药物组合物，所述药物组合物包含有效治疗量的权利要求1中所述的晶型CSV、权利要求7中所述的晶型CSVI或权利要求12中所述的晶型CSVII及药学上可接受的载体或辅料。
  18. 权利要求1中所述的晶型CSV、权利要求7中所述的晶型CSVI或权利要求12中所述的晶型CSVII在制备治疗转甲状腺素蛋白淀粉样病变引发的疾病的药物中的用途。
  19. 权利要求1中所述的晶型CSV、权利要求7中所述的晶型CSVI或权利要求12中所述的晶型CSVII在制备治疗转甲状腺素素蛋白家族性淀粉样多发性神经病变和/或转甲状腺素素蛋白心肌病的药物中的用途。
PCT/CN2020/128376 2019-11-15 2020-11-12 他发米帝司的晶型及其制备方法和用途 WO2021093809A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN202080007389.6A CN113242855B (zh) 2019-11-15 2020-11-12 他发米帝司的晶型及其制备方法和用途
EP20886308.4A EP4059926A4 (en) 2019-11-15 2020-11-12 CRYSTALLINE FORM OF TAFAMIDIS AND PROCESS FOR PRODUCTION AND USE THEREOF
JP2022527915A JP2023503833A (ja) 2019-11-15 2020-11-12 タファミジスの結晶形及びその調製方法及びその使用
US17/392,008 US11795152B2 (en) 2019-11-15 2021-08-02 Crystal form of tafamidis and preparation method therefor and use thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN201911118522.0 2019-11-15
CN201911118522 2019-11-15
CN201911175626 2019-11-26
CN201911175626.5 2019-11-26
CN201911256434.7 2019-12-10
CN201911256434 2019-12-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/392,008 Continuation US11795152B2 (en) 2019-11-15 2021-08-02 Crystal form of tafamidis and preparation method therefor and use thereof

Publications (1)

Publication Number Publication Date
WO2021093809A1 true WO2021093809A1 (zh) 2021-05-20

Family

ID=75912543

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/128376 WO2021093809A1 (zh) 2019-11-15 2020-11-12 他发米帝司的晶型及其制备方法和用途

Country Status (5)

Country Link
US (1) US11795152B2 (zh)
EP (1) EP4059926A4 (zh)
JP (1) JP2023503833A (zh)
CN (1) CN113242855B (zh)
WO (1) WO2021093809A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11523993B1 (en) 2021-11-18 2022-12-13 Nuray Chemicals Private Limited Dosage forms of tafamidis and its pharmaceutically acceptable salt thereof
WO2022264072A1 (en) * 2021-06-16 2022-12-22 Honour Lab Limited Polymorphs of 2-(3,5-dichlorophenyl)-l,3-benzoxazole-6-carboxylic acid
WO2023091534A1 (en) 2021-11-17 2023-05-25 Teva Pharmaceuticals International Gmbh Solid state form of tafamidis

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024023710A1 (en) * 2022-07-28 2024-02-01 Pfizer Inc. Tafamidis pharmaceutical compositions
US11980685B1 (en) 2022-12-23 2024-05-14 Tap Pharmaceuticals, Ag Liquid pharmaceutical formulations of tafamidis
US11878081B1 (en) 2022-12-23 2024-01-23 Tap Pharmaceuticals Ag Pharmaceutical formulations of tafamidis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103781770A (zh) * 2011-09-16 2014-05-07 辉瑞公司 转甲状腺素蛋白解离抑制剂的固体形式
WO2016038500A1 (en) 2014-09-08 2016-03-17 Pfizer Inc. Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
CN107344927A (zh) * 2016-05-05 2017-11-14 苏州晶云药物科技有限公司 Tafamidis葡甲胺盐的晶型E及其制备方法和用途
WO2019175263A1 (en) 2018-03-13 2019-09-19 Azad Pharma Ag New polymorphs and new path to synthesize tafamidis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1587821E (pt) 2002-12-19 2008-09-23 Scripps Research Inst Composições e métodos para estabilização da transtirretina e inibição do enrolamento incorrecto da transtirretina
US20220259162A1 (en) 2019-05-16 2022-08-18 Teva Pharmaceuticals International Gmbh Solid state forms of tafamidis and salts thereof
US20220251052A1 (en) 2019-07-04 2022-08-11 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103781770A (zh) * 2011-09-16 2014-05-07 辉瑞公司 转甲状腺素蛋白解离抑制剂的固体形式
WO2016038500A1 (en) 2014-09-08 2016-03-17 Pfizer Inc. Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
CN106715405A (zh) * 2014-09-08 2017-05-24 辉瑞公司 6‑羧基‑2‑(3,5‑二氯苯基)苯并噁唑的结晶固体形式
CN107344927A (zh) * 2016-05-05 2017-11-14 苏州晶云药物科技有限公司 Tafamidis葡甲胺盐的晶型E及其制备方法和用途
WO2019175263A1 (en) 2018-03-13 2019-09-19 Azad Pharma Ag New polymorphs and new path to synthesize tafamidis

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022264072A1 (en) * 2021-06-16 2022-12-22 Honour Lab Limited Polymorphs of 2-(3,5-dichlorophenyl)-l,3-benzoxazole-6-carboxylic acid
WO2023091534A1 (en) 2021-11-17 2023-05-25 Teva Pharmaceuticals International Gmbh Solid state form of tafamidis
US11523993B1 (en) 2021-11-18 2022-12-13 Nuray Chemicals Private Limited Dosage forms of tafamidis and its pharmaceutically acceptable salt thereof

Also Published As

Publication number Publication date
US11795152B2 (en) 2023-10-24
CN113242855B (zh) 2022-06-28
CN113242855A (zh) 2021-08-10
EP4059926A4 (en) 2022-12-14
US20210363116A1 (en) 2021-11-25
JP2023503833A (ja) 2023-02-01
EP4059926A1 (en) 2022-09-21

Similar Documents

Publication Publication Date Title
WO2021093809A1 (zh) 他发米帝司的晶型及其制备方法和用途
TWI419899B (zh) Ｃｄｄｏ甲基酯之新穎形式
WO2021136477A1 (zh) 化合物i二盐酸盐的共晶及其制备方法和用途
US20220356173A1 (en) Polymorphic forms of kinase inhibitor compound, pharmaceutical composition containing same, preparation method therefor and use thereof
US11066384B2 (en) Crystalline forms of ARN-509, preparation method and use thereof
WO2022007629A1 (zh) 乌帕替尼的晶型及其制备方法和用途
WO2021129465A1 (zh) 一种Resmetirom晶型及其制备方法和用途
WO2020057622A1 (zh) 卡博替尼苹果酸盐晶型及其制备方法和用途
WO2022170864A1 (zh) Belumosudil甲磺酸盐的晶型及其制备方法和用途
US20220002306A1 (en) Crystal form of upadacitinib and preparation method and use thereof
CN114907325A (zh) Belumosudil甲磺酸盐的晶型及其制备方法和用途
WO2021063367A1 (zh) 一种Resmetirom晶型及其制备方法和用途
WO2023208133A1 (zh) 布拉美森盐酸盐的晶型及其制备方法和用途
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
WO2022052822A1 (zh) Resmetirom的晶型及其制备方法和用途
CN114630668B (zh) 一种Aprocitentan晶型及其制备方法和用途
WO2021077994A1 (zh) 一种低氧诱导因子脯氨酰羟化酶抑制剂晶型
WO2019149262A1 (zh) Sb-939的晶型及其制备方法和用途
WO2020151672A1 (zh) 一种达格列净晶型及其制备方法和用途
WO2023143321A1 (zh) 他伐帕敦的晶型及其制备方法和用途
WO2024104268A1 (zh) 艾拉司群二盐酸盐的共晶及其制备方法和用途
US20210300893A1 (en) Crystalline forms of arn-509, preparation method and use thereof
WO2023160579A1 (zh) 一种二肽基肽酶1抑制剂多晶型物及其制备方法和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20886308

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022527915

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020886308

Country of ref document: EP

Effective date: 20220615